<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6316386</article-id><article-id pub-id-type="doi">10.3390/ph11040100</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-11-00100</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>TRP Channels as Drug Targets to Relieve Itch</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Zili</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8967-7522</contrib-id><name><surname>Hu</surname><given-names>Hongzhen</given-names></name><xref rid="c1-pharmaceuticals-11-00100" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pharmaceuticals-11-00100">Department of Anesthesiology, The Center for the Study of Itch, Washington University School of Medicine, St. Louis, MO 63110, USA; <email>zilixie@wustl.edu</email></aff><author-notes><corresp id="c1-pharmaceuticals-11-00100"><label>*</label>Correspondence: <email>hongzhen.hu@wustl.edu</email>; Tel: +1-314-747-4317</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2018</year></pub-date><volume>11</volume><issue>4</issue><elocation-id>100</elocation-id><history><date date-type="received"><day>04</day><month>9</month><year>2018</year></date><date date-type="accepted"><day>03</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 by the authors.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Although acute itch has a protective role by removing irritants to avoid further damage, chronic itch is debilitating, significantly impacting quality of life. Over the past two decades, a considerable amount of stimulating research has been carried out to delineate mechanisms of itch at the molecular, cellular, and circuit levels. There is growing evidence that transient receptor potential (TRP) channels play important roles in itch signaling. The purpose of this review is to summarize our current knowledge about the role of TRP channels in the generation of itch under both physiological and pathological conditions, thereby identifying them as potential drug targets for effective anti-itch therapies.</p></abstract><kwd-group><kwd>TRP channels</kwd><kwd>itch</kwd><kwd>pain</kwd><kwd>TRPA1</kwd><kwd>TRPV1</kwd><kwd>TRPV3</kwd><kwd>TRPV4</kwd><kwd>TRPM8</kwd><kwd>TRPC4</kwd><kwd>agonists</kwd><kwd>antagonists</kwd></kwd-group></article-meta></front><body><sec id="sec1-pharmaceuticals-11-00100"><title>1. Introduction</title><p>Itch, also known as pruritus, is an unpleasant sensation provoking the scratch reflex [<xref rid="B1-pharmaceuticals-11-00100" ref-type="bibr">1</xref>]. Itch is classified as acute or chronic, with the latter defined as pruritus lasting longer than six weeks [<xref rid="B2-pharmaceuticals-11-00100" ref-type="bibr">2</xref>]. Acute itch is often generated locally in the skin by pruritogens and the scratching behavior that is evoked has a protective role by removing irritants. Chronic itch, by contrast, may be maladaptive and leads to significant decrements in quality of life. It is associated with numerous conditions, including atopic eczema, psoriasis, urticaria, inflammatory skin diseases, chronic renal failure, cholestasis, lymphoma, and chronic liver diseases [<xref rid="B3-pharmaceuticals-11-00100" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-11-00100" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceuticals-11-00100" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-11-00100" ref-type="bibr">6</xref>]. Chronic itch remains an unmet medical condition lacking universally effective treatments. Delineating itch mechanisms at the molecular, cellular, and circuit levels is critical to the development of new anti-itch therapeutic strategies.</p><p>The transient receptor potential (TRP) channels comprise 28 members in mammals that can be divided into six subfamilies based on amino acid sequence homology, including TRPA, TRPC, TRPM, TRPML, TRPP, and TRPV [<xref rid="B7-pharmaceuticals-11-00100" ref-type="bibr">7</xref>]. TRP channels respond to a diverse array of thermal, chemical, and mechanical stimuli. They are implicated in many sensory functions including taste, smell, thermoception, touch, osmolarity, and pain [<xref rid="B8-pharmaceuticals-11-00100" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceuticals-11-00100" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-11-00100" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceuticals-11-00100" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-11-00100" ref-type="bibr">12</xref>]. In the past two decades, numerous studies have demonstrated that TRP channels are critically involved in itch sensation under both physiological and pathological conditions [<xref rid="B13-pharmaceuticals-11-00100" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceuticals-11-00100" ref-type="bibr">14</xref>].</p></sec><sec id="sec2-pharmaceuticals-11-00100"><title>2. Cellular Mechanisms of Itch Signaling in the Periphery</title><p>Itch has long been considered a submodality of pain based on observations that local stimulation of the same skin sites at low intensities evokes itch, whereas high intensities cause pain [<xref rid="B15-pharmaceuticals-11-00100" ref-type="bibr">15</xref>]. Pain and itch are now clearly understood to be distinct sensory modalities [<xref rid="B16-pharmaceuticals-11-00100" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-11-00100" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-11-00100" ref-type="bibr">18</xref>]. Pruritogens evoke itch sensation by activating pruriceptors present on free nerve endings of cutaneous primary sensory neurons [<xref rid="B19-pharmaceuticals-11-00100" ref-type="bibr">19</xref>]. Primary sensory neurons are classified into four distinct types based on cell body size and axon myelination: (1) large-diameter, thickly myelinated proprioceptive neurons; (2) large-diameter, myelinated A&#x003b2; low-threshold mechanoreceptors which mediate touch; (3) medium-sized, lightly myelinated A&#x003b4; nociceptive neurons; and (4) small-diameter, unmyelinated C nociceptive neurons that detect noxious stimuli [<xref rid="B19-pharmaceuticals-11-00100" ref-type="bibr">19</xref>]. LaMotte et al. showed that itch-initiating neurons are predominantly C-type neurons with an additional small population of A&#x003b4; neurons [<xref rid="B20-pharmaceuticals-11-00100" ref-type="bibr">20</xref>]. Thus, both pain and itch are transduced by small-diameter dorsal root ganglion (DRG) neurons. However, the two modalities are transduced separately by pain-selective (nociceptive) and itch-selective (pruriceptive) neuronal subpopulations in the skin. This is firmly supported by the finding that the ablation of Mas-related G protein-coupled receptor member A3 (MrgprA3) neurons substantially reduces scratching evoked by multiple pruritogens and under chronic itch conditions, leaving pain sensitivity intact [<xref rid="B21-pharmaceuticals-11-00100" ref-type="bibr">21</xref>].</p><p>In addition to sensory neurons, many other cell types are also involved in itch pathways [<xref rid="B22-pharmaceuticals-11-00100" ref-type="bibr">22</xref>]. For instance, stimulated keratinocytes release numerous inflammatory mediators including thymic stromal lymphopoietin (TSLP), ATP, endothelins, prostaglandins, histamine, nitric oxide, and serotonin which can directly activate or sensitize primary sensory neurons to initiate itch [<xref rid="B22-pharmaceuticals-11-00100" ref-type="bibr">22</xref>]. Similarly, innate immune cells (such as mast cells, neutrophils, macrophages, and dendritic cells) release a versatile ensemble of pruritogenic inflammatory mediators [<xref rid="B23-pharmaceuticals-11-00100" ref-type="bibr">23</xref>]. The interplay between adaptive immune cells and neurons also plays an important role in itch sensation (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>) [<xref rid="B24-pharmaceuticals-11-00100" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceuticals-11-00100" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceuticals-11-00100" ref-type="bibr">26</xref>].</p></sec><sec id="sec3-pharmaceuticals-11-00100"><title>3. TRP Channels and Itch Signaling</title><p>TRP channels are molecular sensors of mechanical, chemical, and thermal environmental cues and are crucially involved in both acute and chronic itch [<xref rid="B19-pharmaceuticals-11-00100" ref-type="bibr">19</xref>,<xref rid="B22-pharmaceuticals-11-00100" ref-type="bibr">22</xref>,<xref rid="B30-pharmaceuticals-11-00100" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-11-00100" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceuticals-11-00100" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceuticals-11-00100" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceuticals-11-00100" ref-type="bibr">34</xref>]. Six TRP channels are now firmly associated with itch generation and transduction (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>).</p><sec id="sec3dot1-pharmaceuticals-11-00100"><title>3.1. TRPA1-Dependent Itch</title><p>TRPA1 is named after the 14 ankyrin repeats in its cytosolic N-termini; it is the sole member of the TRPA subfamily in mammals [<xref rid="B35-pharmaceuticals-11-00100" ref-type="bibr">35</xref>]. TRPA1 is selectively expressed by a subpopulation of small-diameter neurons in dorsal root, trigeminal, and nodose ganglia and keratinocytes [<xref rid="B36-pharmaceuticals-11-00100" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceuticals-11-00100" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-11-00100" ref-type="bibr">38</xref>]. TRPA1 is directly activated by a vast array of noxious and electrophilic compounds (such as allyl isothiocyanate, cinnamaldehyde, allicin, and diallyl disulfide) [<xref rid="B39-pharmaceuticals-11-00100" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceuticals-11-00100" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-11-00100" ref-type="bibr">41</xref>], and numerous endogenous reactive oxygen species (such as hydrogen peroxide and 4-hydroxynonenal (4-HNE) [<xref rid="B42-pharmaceuticals-11-00100" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-11-00100" ref-type="bibr">43</xref>]. It can also be activated by the transition metal ion Zn<sup>2+</sup>, leading to acute pain [<xref rid="B44-pharmaceuticals-11-00100" ref-type="bibr">44</xref>].</p><p>Itch-related G protein-coupled receptors (GPCRs), including the bile acid receptor TGR5, the TSLP receptor, and the MrgprA3 and MrgprC11, can positively modulate TRPA1 [<xref rid="B45-pharmaceuticals-11-00100" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceuticals-11-00100" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceuticals-11-00100" ref-type="bibr">47</xref>]. Many pharmacological blockade and genetic ablation studies have shown that TRPA1 is a critical downstream mediator of GPCR signaling in different mouse models of acute and chronic itch.</p><sec id="sec3dot1dot1-pharmaceuticals-11-00100"><title>3.1.1. TRPA1 in Histamine-Independent Itch Induced by Chloroquine (CQ) and Bovine Adrenal Medulla 8&#x02013;22 Peptide (BAM8-22)</title><p>Antihistamines are useful for treating many types of acute itch, but generally ineffective under many chronic itch conditions, which are histamine-independent. CQ is commonly used to treat malaria and evokes severe itching as a major side effect, which is especially common among black Africans. Liu et al. found that CQ activated MrgprA3 to trigger histamine-independent itch [<xref rid="B46-pharmaceuticals-11-00100" ref-type="bibr">46</xref>]. Both loss- and gain-of-function studies further demonstrated that MrgprA3 was required for CQ-induced itch in mice [<xref rid="B46-pharmaceuticals-11-00100" ref-type="bibr">46</xref>]. Similarly, MrgprC11 was required for BAM8-22-induced acute itch in mice [<xref rid="B46-pharmaceuticals-11-00100" ref-type="bibr">46</xref>]. Moreover, Wilson et al. showed that TRPA1 was a downstream target of both MrgprA3 and MrgprC11 signaling and required for both CQ- and BAM8-22-induced itch [<xref rid="B48-pharmaceuticals-11-00100" ref-type="bibr">48</xref>]. However, distinct mechanisms are involved in MrgprA3 and MrgprC11 signaling to activate TRPA1: G&#x003b2;&#x003b3; signaling is required for MrgprA3 and phospholipase C (PLC) signaling is required for MrgprC11 (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>) [<xref rid="B48-pharmaceuticals-11-00100" ref-type="bibr">48</xref>]. Interestingly, a recent study demonstrated that CQ-evoked primary afferent firing ex vivo, and scratching responses in vivo, were not significantly different between wild-type and TRPA1-deficient mice. Instead, chloride channels may play a more important role in CQ-induced increases in sensory neuron excitability and scratching [<xref rid="B49-pharmaceuticals-11-00100" ref-type="bibr">49</xref>].</p></sec><sec id="sec3dot1dot2-pharmaceuticals-11-00100"><title>3.1.2. TRPA1 in 5-Hydroxytryptamine (5-HT)-Induced Itch</title><p>5-HT is released by tissue-resident mast cells, which can in turn activate pruriceptive afferents [<xref rid="B50-pharmaceuticals-11-00100" ref-type="bibr">50</xref>]. Pruritogenic 5-HT signaling occurs in some localized or systemic diseases, such as atopic dermatitis (AD), cholestasis, and psoriasis [<xref rid="B51-pharmaceuticals-11-00100" ref-type="bibr">51</xref>]. Morita et al. found that both HTR7 and TRPA1 were required for 5-HT-induced itch because mice lacking HTR7 or TRPA1 had severely reduced scratching responses in both 5-HT-induced acute itch and in a mouse model of AD (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>) [<xref rid="B52-pharmaceuticals-11-00100" ref-type="bibr">52</xref>]. On the other hand, Akiyama et al. showed that 5-HT-induced acute scratching required TRPV4 but not TRPA1 or TRPV1 because scratching was significantly diminished in TRPV4 knockout (KO) mice, but unaffected by genetic ablation of either TRPA1 or TRPV1 function [<xref rid="B27-pharmaceuticals-11-00100" ref-type="bibr">27</xref>].</p></sec><sec id="sec3dot1dot3-pharmaceuticals-11-00100"><title>3.1.3. TRPA1 in Cholestatic Pruritus</title><p>Patients with cholestatic or other obstructive liver diseases often suffer severe pruritus caused by increased levels of bile acid in the circulation and skin [<xref rid="B53-pharmaceuticals-11-00100" ref-type="bibr">53</xref>]. Indeed, bile acid chelators can relieve cholestatic pruritus, whereas direct intradermal injections of bile acid cause scratching in mice [<xref rid="B54-pharmaceuticals-11-00100" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceuticals-11-00100" ref-type="bibr">55</xref>]. Lieu et al. demonstrated that TGR5 activates and sensitizes TRPA1 by a G&#x003b2;&#x003b3;- and PKC-dependent mechanism and that bile acid-induced itch requires TRPA1 (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>) [<xref rid="B45-pharmaceuticals-11-00100" ref-type="bibr">45</xref>]. Both pharmacological inhibition and genetic ablation of TRPA1 function prevented the bile acid-stimulated release of the pruritogenic neuropeptide gastrin-releasing peptide (GRP) and reduced the bile acid-elicited scratching. Moreover, spontaneous scratching was exacerbated in transgenic mice overexpressing TGR5, which was prevented by the administration of a TRPA1 antagonist [<xref rid="B45-pharmaceuticals-11-00100" ref-type="bibr">45</xref>]. Thus, TRPA1 and TGR5 are potential drug targets for alleviating itch in patients with cholestatic and other obstructive liver diseases.</p></sec><sec id="sec3dot1dot4-pharmaceuticals-11-00100"><title>3.1.4. TRPA1 in Itch Associated with AD</title><p>The protease-activated receptor 2 (PAR2) plays an important role in keratinocyte TSLP production, and there is a correlation between PAR2 activity and TSLP expression in the skin of AD patients and in mouse models of atopic diseases [<xref rid="B56-pharmaceuticals-11-00100" ref-type="bibr">56</xref>]. Interestingly, TSLP over-expression in keratinocytes triggers robust itch-evoked scratching and the development of an AD-like skin phenotype in mice [<xref rid="B57-pharmaceuticals-11-00100" ref-type="bibr">57</xref>]. Wilson et al. reported that PAR2 evoked robustly increased expression of TSLP in keratinocytes and that TSLP acted directly on a TRPA1-positive subset of sensory neurons to produce robust scratching via TSLP receptor (TSLPR) signaling [<xref rid="B47-pharmaceuticals-11-00100" ref-type="bibr">47</xref>]. Subcutaneous TSLP injections in wild-type mice evoked scratching which was significantly attenuated by functional ablation of TRPA1 and by genetic ablation of IL7R&#x003b1; which formed a heterodimeric receptor with TSLPR, but not by functional ablation of TRPV1. PLC signaling was required for the functional coupling between TSLPR signaling and TRPA1 activation (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>) [<xref rid="B47-pharmaceuticals-11-00100" ref-type="bibr">47</xref>].</p></sec><sec id="sec3dot1dot5-pharmaceuticals-11-00100"><title>3.1.5. TRPA1 in Itch Induced by Extracellular miRNAs</title><p>Chronic itch is a major symptom of cutaneous T cell lymphoma [<xref rid="B58-pharmaceuticals-11-00100" ref-type="bibr">58</xref>]. Intradermal inoculation of human Myla cells can induce lymphoma associated with intense itching in immune-deficient mice [<xref rid="B59-pharmaceuticals-11-00100" ref-type="bibr">59</xref>]. Interestingly, lymphoma-associated itch is suppressed by a miRNA-711 inhibitor and a blocking peptide that disrupts miRNA-711/TRPA1 interaction. Moreover, extracellular miRNA directly activates TRPA1 on sensory neurons to induce TRPA1-depedent itch without causing pain in naive mice (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>) [<xref rid="B59-pharmaceuticals-11-00100" ref-type="bibr">59</xref>]. These findings demonstrated an unconventional physiological role of extracellular naked miRNAs as pruritogens and TRPA1 modulators [<xref rid="B59-pharmaceuticals-11-00100" ref-type="bibr">59</xref>,<xref rid="B60-pharmaceuticals-11-00100" ref-type="bibr">60</xref>].</p></sec></sec><sec id="sec3dot2-pharmaceuticals-11-00100"><title>3.2. TRPV1-Dependent Itch</title><p>TRPV1 belongs to a subfamily of temperature-sensitive TRP channels, also called &#x0201c;ThermoTRPs&#x0201d; [<xref rid="B61-pharmaceuticals-11-00100" ref-type="bibr">61</xref>]. TRPV1 is activated by noxious temperatures (&#x0003e;43 &#x000b0;C) [<xref rid="B62-pharmaceuticals-11-00100" ref-type="bibr">62</xref>]. In addition, TRPV1 is activated by capsaicin, low pH, and numerous molecules associated with inflammation and tissue damage such as bradykinin, prokineticin, prostaglandins, anandamide, and retinoids [<xref rid="B22-pharmaceuticals-11-00100" ref-type="bibr">22</xref>,<xref rid="B63-pharmaceuticals-11-00100" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceuticals-11-00100" ref-type="bibr">64</xref>,<xref rid="B65-pharmaceuticals-11-00100" ref-type="bibr">65</xref>].</p><p>Histamine is one of the best-known endogenous pruritogens [<xref rid="B66-pharmaceuticals-11-00100" ref-type="bibr">66</xref>]. Applied to human skin, histamine causes local vasodilation and gives rise to the characteristic triple response: redness, flare, and swelling, accompanied by intense itching [<xref rid="B67-pharmaceuticals-11-00100" ref-type="bibr">67</xref>]. Among four histamine receptors (including the histamine receptors H1R, H2R, H3R, and H4R), H1R and H4R are expressed by pruriceptive DRG neurons and mediate histamine-induced itch [<xref rid="B68-pharmaceuticals-11-00100" ref-type="bibr">68</xref>]. TRPV1 plays a crucial role in histamine-induced itch via coupling with H1R-mediated signaling [<xref rid="B69-pharmaceuticals-11-00100" ref-type="bibr">69</xref>]. Histamine activates inward currents only when H1R and TRPV1 are co-expressed heterologously, and histamine evokes Ca<sup>2+</sup> influxes in sensory neurons isolated from wild-type but not TRPV1 KO mice [<xref rid="B69-pharmaceuticals-11-00100" ref-type="bibr">69</xref>]. Importantly, TRPV1 KO mice have markedly reduced histamine-induced scratching compared to wild-type mice [<xref rid="B69-pharmaceuticals-11-00100" ref-type="bibr">69</xref>]. In addition, TRPV1 may be involved in histamine-induced itch mediated by H4R (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>) [<xref rid="B70-pharmaceuticals-11-00100" ref-type="bibr">70</xref>].</p><p>Besides histamine-dependent itch, direct activation of TRPV1 by the pruritogen, cyclic phosphatidic acid, also evokes robust scratching responses [<xref rid="B71-pharmaceuticals-11-00100" ref-type="bibr">71</xref>]. The naturally occurring monounsaturated fatty acid and oleic acid antagonize TRPV1 by interacting with the vanilloid (capsaicin)-binding pocket and promoting stabilization of a closed state conformation. Importantly, oleic acid inhibits cyclic phosphatidic acid-induced activation of TRPV1 in vitro as well as TRPV1-dependent pain and itch responses in vivo [<xref rid="B71-pharmaceuticals-11-00100" ref-type="bibr">71</xref>], further highlighting the importance of TRPV1 in itch sensation (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>).</p></sec><sec id="sec3dot3-pharmaceuticals-11-00100"><title>3.3. Itch Mediated by Both TRPA1 and TRPV1</title><p>Lysophosphatidic acid (LPA) is another proposed itch mediator besides bile acid in cholestatic pruritus [<xref rid="B72-pharmaceuticals-11-00100" ref-type="bibr">72</xref>]. Intradermal injections of LPA provoke scratching behaviors in rodents [<xref rid="B72-pharmaceuticals-11-00100" ref-type="bibr">72</xref>,<xref rid="B73-pharmaceuticals-11-00100" ref-type="bibr">73</xref>,<xref rid="B74-pharmaceuticals-11-00100" ref-type="bibr">74</xref>]. Both TRPA1 and TRPV1 are implicated in LPA-induced itch (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>). Genetic ablation of either TRPV1 or TRPA1 reduces LPA-induced activation of DRG neurons and scratching responses elicited by intradermal LPA injections [<xref rid="B74-pharmaceuticals-11-00100" ref-type="bibr">74</xref>]. LPA directly activates TRPA1 through interactions with positive charged amino acids KK672&#x02013;673/KR977&#x02013;978 and K710 [<xref rid="B74-pharmaceuticals-11-00100" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceuticals-11-00100" ref-type="bibr">75</xref>] on the cytosolic sites of the protein.</p><p>Squaric acid dibutylester (SADBE) is a small molecule hapten commonly used for treating alopecia areata and warts that often causes contact hypersensitivity (CHS) in humans [<xref rid="B76-pharmaceuticals-11-00100" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceuticals-11-00100" ref-type="bibr">77</xref>]. SADBE effectively induces CHS in a mouse model of allergic contact dermatitis (ACD) associated with spontaneous scratching behaviors [<xref rid="B78-pharmaceuticals-11-00100" ref-type="bibr">78</xref>]. Recently, Feng et al. found that both TRPA1 and TRPV1 were involved in generating spontaneous scratching in SADBE-induced ACD model in mice (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>) [<xref rid="B30-pharmaceuticals-11-00100" ref-type="bibr">30</xref>]. Unexpectedly, TRPV1 but not TRPA1 protected against the SADBE-induced skin inflammation, suggesting that chronic skin inflammation and persistent itch in SADBE-induced CHS were mediated by distinct molecular mechanisms. These results suggested that extreme care should be taken when applying TRP channel blockers to treat chronic itch because they might also promote skin inflammation.</p><p>T-cell-derived Th2 cytokine IL31 is upregulated in itch-related cutaneous T cell lymphoma and AD in humans [<xref rid="B4-pharmaceuticals-11-00100" ref-type="bibr">4</xref>,<xref rid="B79-pharmaceuticals-11-00100" ref-type="bibr">79</xref>]. The neutralization of interleukin-31 (IL-31) by anti-interleukin-31 antibodies ameliorates scratching behavior in the NC/Nga mouse model of AD (a strain of Japanese fancy mice) [<xref rid="B80-pharmaceuticals-11-00100" ref-type="bibr">80</xref>]. Moreover, cutaneous or intrathecal injections of IL-31 provoke intense itching, and IL-31 concentration is increased significantly in AD-like skin preparations in mice [<xref rid="B81-pharmaceuticals-11-00100" ref-type="bibr">81</xref>]. Both human and mouse DRG neurons express IL-31RA, primarily in neurons that co-express TRPV1. Compared with respective control mice, IL-31-induced itch response is significantly attenuated in either TRPV1 or TRPA1 KO mice [<xref rid="B81-pharmaceuticals-11-00100" ref-type="bibr">81</xref>]. Taken together, it is likely both TRPA1 and TRPV1 are involved in IL-31-induced itch (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>). Thus, both TRPA1 and TRPV1 represent possible therapeutic targets for the management of Th2 cytokine-mediated itch.</p><p>Sphingosine 1-phosphate (S1P) is an important signaling sphingolipid involved in both itch and pain signaling [<xref rid="B82-pharmaceuticals-11-00100" ref-type="bibr">82</xref>,<xref rid="B83-pharmaceuticals-11-00100" ref-type="bibr">83</xref>,<xref rid="B84-pharmaceuticals-11-00100" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceuticals-11-00100" ref-type="bibr">85</xref>]. A recent study showed that low concentrations of S1P selectively evoked acute itch, and that high concentrations of S1P caused both pain and itch [<xref rid="B82-pharmaceuticals-11-00100" ref-type="bibr">82</xref>]. S1P receptor 3 (S1PR3) appeared to be the sole mediator of both S1P-induced itch and pain responses through promoting excitability of different primary afferents: S1PR3 and TRPA1 co-existed in a subset of pruriceptors, but S1PR3 was co-expressed with TRPV1 in a subset of heat nociceptors. In line with these unique expression patterns, TRPA1 mediated S1P-induced itch behaviors and TRPV1 mediated S1P-elicited acute pain and heat hypersensitivity (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>). These findings suggested that distinct cellular and molecular mechanisms mediated S1P-induced itch and pain sensations [<xref rid="B82-pharmaceuticals-11-00100" ref-type="bibr">82</xref>].</p></sec><sec id="sec3dot4-pharmaceuticals-11-00100"><title>3.4. TRPV3-Dependent Itch</title><p>TRPV3 is another ThermoTRP that is activated by temperatures &#x0003e;33 &#x000b0;C [<xref rid="B86-pharmaceuticals-11-00100" ref-type="bibr">86</xref>]. It is activated by many endogenous ligands (such as farnesyl pyrophosphate) [<xref rid="B87-pharmaceuticals-11-00100" ref-type="bibr">87</xref>], synthetic compounds (such as 2-aminoethoxydiphenyl borate (2-APB)) [<xref rid="B88-pharmaceuticals-11-00100" ref-type="bibr">88</xref>], and some natural compounds (such as carvacrol, menthol, thymol, eugenol, and citral) [<xref rid="B89-pharmaceuticals-11-00100" ref-type="bibr">89</xref>,<xref rid="B90-pharmaceuticals-11-00100" ref-type="bibr">90</xref>,<xref rid="B91-pharmaceuticals-11-00100" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceuticals-11-00100" ref-type="bibr">92</xref>].</p><p>Unlike TRPA1 and TRPV1 channels, which are mainly expressed by primary sensory neurons, TRPV3 is primarily expressed by mouse skin keratinocytes and oral and nasal epithelia, although TRPV3 is also detected in human DRG neurons (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>) [<xref rid="B93-pharmaceuticals-11-00100" ref-type="bibr">93</xref>,<xref rid="B94-pharmaceuticals-11-00100" ref-type="bibr">94</xref>,<xref rid="B95-pharmaceuticals-11-00100" ref-type="bibr">95</xref>]. TRPV3 expression is increased in keratinocytes from AD lesions and patients suffering from postburn pruritus [<xref rid="B96-pharmaceuticals-11-00100" ref-type="bibr">96</xref>,<xref rid="B97-pharmaceuticals-11-00100" ref-type="bibr">97</xref>], but not in biopsies from chronic idiopathic pruritus (CIP) patients [<xref rid="B98-pharmaceuticals-11-00100" ref-type="bibr">98</xref>].</p><p>TRPV3 is widely involved in skin barrier function, hair growth, skin inflammation, pain, and itch [<xref rid="B13-pharmaceuticals-11-00100" ref-type="bibr">13</xref>,<xref rid="B99-pharmaceuticals-11-00100" ref-type="bibr">99</xref>,<xref rid="B100-pharmaceuticals-11-00100" ref-type="bibr">100</xref>,<xref rid="B101-pharmaceuticals-11-00100" ref-type="bibr">101</xref>]. The role of TRPV3 in itch sensation attracts a great deal of attention since Asakawa et al. first reported that the Gly573Ser substitution in Trpv3 gene (TRPV3<italic><sup>Gly573Ser</sup></italic>) in DS-Nh mice produced a hairlessness phenotype and that these mice also developed allergic and pruritic dermatitis [<xref rid="B102-pharmaceuticals-11-00100" ref-type="bibr">102</xref>]. Both G573S and G573C mutations of murine TRPV3 are gain-of-function mutations promoting basal TRPV3 channel activity and enhancing responses to TRPV3 ligands compared to wild-type TRPV3 [<xref rid="B103-pharmaceuticals-11-00100" ref-type="bibr">103</xref>]. These mutations drive constitutive TRPV3 activity under normal physiological conditions, subsequently altering ion homeostasis and membrane potentials of skin keratinocytes, leading to hair loss and dermatitis-like skin phenotypes.</p><p>Gain-of-function mutations in human TRPV3 from patients with Olmsted syndrome (OS) suggest a role of TRPV3 in human itch signaling [<xref rid="B104-pharmaceuticals-11-00100" ref-type="bibr">104</xref>]. OS is a rare skin disease characterized by palmoplantar, alopecia, onychodystrophy, and severe itching [<xref rid="B105-pharmaceuticals-11-00100" ref-type="bibr">105</xref>]. To date, mutations of five different amino acid residues in TRPV3 have been associated with OS from more than 70 cases, including p.Gly568, p.Gly573, p.Leu673, p.Trp692, and p.Asn415_Arg416 [<xref rid="B106-pharmaceuticals-11-00100" ref-type="bibr">106</xref>].</p><p>Although TRPV3 mutants in both DS-Nh mice and OS patients display itch symptoms, it remains unclear whether itch arises directly from TRPV3-mediated signaling or secondarily through TRPV3-mediated skin pathogenesis. Direct evidence supporting the involvement of TRPV3 in itch signaling is currently lacking. It is possible that additional cellular and molecular mechanisms are required to produce itch in TRPV3 mutants in vivo, besides elevated basal activity and altered ligand-evoked responses.</p></sec><sec id="sec3dot5-pharmaceuticals-11-00100"><title>3.5. TRPV4-Dependent Itch</title><p>TRPV4 is another ThermoTRP activated at temperatures between 27 &#x000b0;C and 35 &#x000b0;C [<xref rid="B107-pharmaceuticals-11-00100" ref-type="bibr">107</xref>]. TRPV4 expression occurs in skin, kidney, urinary bladder, and DRG [<xref rid="B108-pharmaceuticals-11-00100" ref-type="bibr">108</xref>,<xref rid="B109-pharmaceuticals-11-00100" ref-type="bibr">109</xref>]. Interestingly, photodermatitis and sunburn are accompanied by symptoms of pain and enhanced epidermal expression of TRPV4 [<xref rid="B110-pharmaceuticals-11-00100" ref-type="bibr">110</xref>], suggesting TRPV4 may be a sunburn pain mediator.</p><p>Recently, Akiyama et al. reported that TRPV4 played an important role in 5-HT-induced acute itch because 5-HT- but not the peptide Ser-Leu-Ile-Gly-Arg-Leu (SLIGRL)- or histamine-evoked scratching was reduced in TRPV4 KO mice, compared with wild-type mice [<xref rid="B27-pharmaceuticals-11-00100" ref-type="bibr">27</xref>]. However, Chen et al. showed that scratching responses elicited by all histaminergic pruritogens including histamine, compound 48/80, and ET-1 were significantly attenuated in both global and keratinocyte-specific TRPV4 KO mice compared with their respective controls [<xref rid="B28-pharmaceuticals-11-00100" ref-type="bibr">28</xref>]. In line with these findings, Kim et al. showed that TRPV4 was required for histamine-induced itch because TRPV4 KO mice exhibited significant reductions in scratching responses to histamine compared with wild-type littermates [<xref rid="B29-pharmaceuticals-11-00100" ref-type="bibr">29</xref>].</p><p>The role of TRPV4 in scratching responses induced by non-histaminergic pruritogen CQ is controversial. Akiyama et al. showed that the number of CQ-induced scratching bouts was significantly increased in global TRPV4 KO mice compared with wild-type mice [<xref rid="B27-pharmaceuticals-11-00100" ref-type="bibr">27</xref>]. In contrast, Chen et al. found that CQ-evoked scratching was unaffected by global TRPV4 KO or skin-specific TRPV4 KO, compared with their respective controls [<xref rid="B28-pharmaceuticals-11-00100" ref-type="bibr">28</xref>]. Even more surprisingly, Kim et al. showed that global TRPV4 KO mice exhibited a significant attenuation in scratching responses to CQ compared with wild-type littermates [<xref rid="B29-pharmaceuticals-11-00100" ref-type="bibr">29</xref>].</p><p>Besides involvement in acute itch, Luo et al. reported that lineage-specific deletion of TRPV4 in macrophages and keratinocytes reduced both allergic and nonallergic chronic itch in mice [<xref rid="B98-pharmaceuticals-11-00100" ref-type="bibr">98</xref>]. Additionally, TRPV4 expression in skin biopsies from CIP patients was significantly increased compared with healthy controls. Taken together, the evidence implicates TRPV4 in both allergic and non-allergic chronic itch, and thus represents a potential therapeutic target for both conditions.</p></sec><sec id="sec3dot6-pharmaceuticals-11-00100"><title>3.6. TRPM8 in Itch Modulation</title><p>TRPM8 is activated by cool and cold temperatures between 8 &#x000b0;C and 28 &#x000b0;C [<xref rid="B111-pharmaceuticals-11-00100" ref-type="bibr">111</xref>,<xref rid="B112-pharmaceuticals-11-00100" ref-type="bibr">112</xref>]. It can also be activated by several natural compounds that can lead to a cooling sensation, including menthone, menthol, and eucalyptol [<xref rid="B113-pharmaceuticals-11-00100" ref-type="bibr">113</xref>,<xref rid="B114-pharmaceuticals-11-00100" ref-type="bibr">114</xref>]. TRPM8 is expressed by keratinocytes and a subset of primary afferent sensory neurons and serves as a cold sensor in vivo [<xref rid="B115-pharmaceuticals-11-00100" ref-type="bibr">115</xref>,<xref rid="B116-pharmaceuticals-11-00100" ref-type="bibr">116</xref>,<xref rid="B117-pharmaceuticals-11-00100" ref-type="bibr">117</xref>].</p><p>Pain, itch, and cold sensations are closely related. Under certain circumstances, pain can inhibit itch and cooling can relieve both pain and itch [<xref rid="B118-pharmaceuticals-11-00100" ref-type="bibr">118</xref>,<xref rid="B119-pharmaceuticals-11-00100" ref-type="bibr">119</xref>,<xref rid="B120-pharmaceuticals-11-00100" ref-type="bibr">120</xref>,<xref rid="B121-pharmaceuticals-11-00100" ref-type="bibr">121</xref>,<xref rid="B122-pharmaceuticals-11-00100" ref-type="bibr">122</xref>]. Cooling by applying ice or cold water is a commonly used method to relieve itch [<xref rid="B121-pharmaceuticals-11-00100" ref-type="bibr">121</xref>]. Emerging evidence suggests that TRPM8 activation reduces itch, whereas some specific TRPM8 activators can aggravate itch [<xref rid="B123-pharmaceuticals-11-00100" ref-type="bibr">123</xref>,<xref rid="B124-pharmaceuticals-11-00100" ref-type="bibr">124</xref>]. Icilin, a potent TRPM8 activator, is effective in reducing vulva pruritus resulting from <italic>lichen sclerosus et atrophicus</italic> [<xref rid="B125-pharmaceuticals-11-00100" ref-type="bibr">125</xref>]. Similarly, menthol and cooling inhibit histamine- and lichenification-evoked itch in humans [<xref rid="B126-pharmaceuticals-11-00100" ref-type="bibr">126</xref>]. Recently, Palkar et al. found that cooling and the cold mimetic menthol could inhibit both histaminergic and non-histaminergic itch pathways. Itch inhibition by cooling required the participation of TRPM8 and functional intact TRPM8-expressing afferent neurons [<xref rid="B120-pharmaceuticals-11-00100" ref-type="bibr">120</xref>]. More importantly, dry skin-associated chronic itch could also be ameliorated by cooling in mice [<xref rid="B120-pharmaceuticals-11-00100" ref-type="bibr">120</xref>]. These results suggested that TRPM8 was an itch modulator and that the TRPM8-mediated counter-stimulus activated a specific neural circuit that represented a potential cellular mechanism that could be exploited for chronic itch treatments.</p></sec><sec id="sec3dot7-pharmaceuticals-11-00100"><title>3.7. TRPC4-Dependent Itch</title><p>Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly used antidepressants prescribed and well known to elicit adverse skin reactions including rashes, urticaria, and pruritus with unknown mechanisms [<xref rid="B127-pharmaceuticals-11-00100" ref-type="bibr">127</xref>]. Recently, Lee et al. reported that HTR2B and TRPC4 were involved in SSRI-evoked pruritus [<xref rid="B128-pharmaceuticals-11-00100" ref-type="bibr">128</xref>]. Subcutaneous injections of 1 mM sertraline into mice evoked robust acute scratching, and mice treated with siRNA targeting HTR2B displayed significant reductions in sertraline-evoked itch behavior compared with mice receiving a control siRNA. Sertraline-evoked itch is also significantly attenuated by genetic ablation of TRPC4, but not TRPA1 or TRPV1 function, implicating the role of TRPC4 in SSRI-induced itch (<xref ref-type="fig" rid="pharmaceuticals-11-00100-f001">Figure 1</xref>). It has also been reported that cutaneous administration of 100 &#x003bc;M sertraline induced itch through serotonin receptor 7 (HTR7) using genetic ablation and pharmacological inhibition approaches [<xref rid="B52-pharmaceuticals-11-00100" ref-type="bibr">52</xref>]. Thus, SSRI-evoked itch may arise through multiple pathways, one of which includes TRPC4. These recent findings raise the question of whether TRPC4 mediates other conditions in which pruritogenic 5-HT signaling can occur, such as AD, cholestasis, and psoriasis.</p></sec></sec><sec id="sec4-pharmaceuticals-11-00100"><title>4. Ligands Commonly Used for Studying Itch-Related TRP Channels</title><p>TRP channel ligands are crucial tools for revealing the biological function of TRP channels in itch sensation (<xref rid="pharmaceuticals-11-00100-t001" ref-type="table">Table 1</xref>). Additionally, antagonists of TRPA1, TRPV1, TRPV3, TRPV4, and TRPC4 and agonists of TRPM8 can be potential drugs for treating itch and other TRP-related diseases. Therefore, the identification of potent and selective TRP channel ligands is of great importance in developing effective itch therapies.</p><sec id="sec4dot1-pharmaceuticals-11-00100"><title>4.1. TRPA1 Antagonists</title><p>HC-030031 is the most widely used TRPA1 blocker. It inhibits AITC- and formalin-evoked Ca<sup>2+</sup> influx with IC<sub>50</sub> values of 6.2 &#x000b1; 0.2 and 5.3 &#x000b1; 0.2 &#x003bc;M, respectively [<xref rid="B129-pharmaceuticals-11-00100" ref-type="bibr">129</xref>]. However, when tested in radioligand binding assays at 10 &#x003bc;M concentration, HC-030031 also displays activities against several other membrane proteins including sodium channels (40%) and sigma receptors (37%) [<xref rid="B147-pharmaceuticals-11-00100" ref-type="bibr">147</xref>]. HC030031 has been widely used to explore the TRPA1 function in itch. The application of 30 mg/kg HC030031 can alleviate scratching responses induced by the selective PAR4 agonist AYPGKF-NH<sub>2</sub> (AYP) by 55% in mice [<xref rid="B148-pharmaceuticals-11-00100" ref-type="bibr">148</xref>]. Similarly, the number of scratching bouts in a mouse model of AD is significantly attenuated after the administration of HC-030031, which persists for 1 h [<xref rid="B149-pharmaceuticals-11-00100" ref-type="bibr">149</xref>]. HC030031 also inhibits scratching responses in ACD in mice, elicited by the exposure to haptens including oxazolone and urushiol, the contact allergen of poison ivy [<xref rid="B150-pharmaceuticals-11-00100" ref-type="bibr">150</xref>]. Moreover, HC030031 also suppresses scratching responses induced by the chemoattractant leukotriene B<sub>4</sub> (LTB<sub>4</sub>) in female CD1 mice [<xref rid="B151-pharmaceuticals-11-00100" ref-type="bibr">151</xref>].</p><p>A-967079 is another commonly used TRPA1 antagonist [<xref rid="B130-pharmaceuticals-11-00100" ref-type="bibr">130</xref>]. It inhibits mouse TRPA1 with an IC<sub>50</sub> value of 0.3 &#x003bc;M [<xref rid="B130-pharmaceuticals-11-00100" ref-type="bibr">130</xref>]. A-967079 is &#x0003e;1000-fold selective over other TRP channels and &#x0003e;150-fold selective over 75 other tested proteins [<xref rid="B130-pharmaceuticals-11-00100" ref-type="bibr">130</xref>]. A 3D structure of human TRPA1 in complex with A-967079 shows that two amino acid residues (S873 and T874) located in the fifth transmembrane domain of TRPA1 play important roles in interacting with A-967079 [<xref rid="B152-pharmaceuticals-11-00100" ref-type="bibr">152</xref>]. A-967079 effectively suppresses spontaneous scratching in mouse models of ACD chemically induced by SADBE, oxazolone, urushiol, poison ivy, and 2,4-dinitrochlorobenzene (DNCB) [<xref rid="B30-pharmaceuticals-11-00100" ref-type="bibr">30</xref>,<xref rid="B150-pharmaceuticals-11-00100" ref-type="bibr">150</xref>,<xref rid="B153-pharmaceuticals-11-00100" ref-type="bibr">153</xref>].</p><p>AP18, identified as a potent and selective TRPA1 inhibitor, suppresses Ca<sup>2+</sup> responses evoked by 50 &#x003bc;M cinnamaldehyde with IC<sub>50</sub> values of 3.1 &#x003bc;M and 4.5 &#x003bc;M for human and mouse TRPA1, respectively [<xref rid="B131-pharmaceuticals-11-00100" ref-type="bibr">131</xref>]. Importantly, at concentrations up to 50 &#x003bc;M, AP18 is unable to appreciably block activation of TRPV1, TRPV2, TRPV3, TRPV4, or TRPM8 [<xref rid="B131-pharmaceuticals-11-00100" ref-type="bibr">131</xref>]. Schenkel et al. identified compound 4 as a TRPA1 antagonist by using high-throughput screening [<xref rid="B132-pharmaceuticals-11-00100" ref-type="bibr">132</xref>]. Although compound 4 shows antagonist activity only at concentrations up to 25 &#x003bc;M, a series of modifications to compound 4 led to the discovery of compound 27 (AM-0902) [<xref rid="B132-pharmaceuticals-11-00100" ref-type="bibr">132</xref>]. Compound 27 is a potent and selective TRPA1 antagonist with an IC<sub>50</sub> value of 0.024 &#x003bc;M for human TRPA1 and it exhibits no significant activity against TRPV1, TRPV3, TRPV4, or TRPM8 [<xref rid="B132-pharmaceuticals-11-00100" ref-type="bibr">132</xref>]. However, neither AP18 nor AM-0902 have yet been used for itch studies.</p></sec><sec id="sec4dot2-pharmaceuticals-11-00100"><title>4.2. TRPV1 Antagonists</title><p>AMG9810 is the most widely used TRPV1 inhibitor. It is a competitive antagonist of capsaicin with an IC<sub>50</sub> value of 24.5 &#x000b1; 15.7 nM for human TRPV1 [<xref rid="B133-pharmaceuticals-11-00100" ref-type="bibr">133</xref>]. It blocks all known modes of TRPV1 activation, including protons, heat, and endogenous ligands [<xref rid="B133-pharmaceuticals-11-00100" ref-type="bibr">133</xref>]. AMG9810 blocks capsaicin-evoked depolarization and calcitonin gene-related peptide (CGRP) release in cultures of rat DRG neurons [<xref rid="B133-pharmaceuticals-11-00100" ref-type="bibr">133</xref>]. A recent study demonstrated that AMG9810 suppressed itch behavior elicited by subcutaneous injections of immepip dihydrobromide, a selective histamine H4 receptor agonist [<xref rid="B70-pharmaceuticals-11-00100" ref-type="bibr">70</xref>].</p><p>By using high-throughput screening of a large chemical library, Gunthorpe et al. identified a potent and selective TRPV1 antagonist, SB366791 [<xref rid="B134-pharmaceuticals-11-00100" ref-type="bibr">134</xref>]. SB366791 inhibits human TRPV1 and rat TRPV1 currents activated by 1 &#x003bc;M capsaicin with IC<sub>50</sub> values of 5.7 &#x000b1; 1.2 nM and 7.5 &#x000b1; 1.8 nM, respectively [<xref rid="B134-pharmaceuticals-11-00100" ref-type="bibr">134</xref>]. SB366791 also inhibits acid- and heat-activated TRPV1 current. Importantly, 1 &#x003bc;M SB-366791 shows little or no activity to 47 other ion channels and G protein-coupled receptors [<xref rid="B134-pharmaceuticals-11-00100" ref-type="bibr">134</xref>]. SB366791 is a potent inhibitor of itch responses induced by PAR4 or PAR2 activation in mice [<xref rid="B148-pharmaceuticals-11-00100" ref-type="bibr">148</xref>,<xref rid="B154-pharmaceuticals-11-00100" ref-type="bibr">154</xref>].</p><p>TRPV1 antagonists have also been tested in clinical trials as anti-itch drugs. PAC-14028 is a potent TRPV1 inhibitor with an IC<sub>50</sub> value of 55.0 &#x000b1; 7.1 nM against capsaicin-induced calcium influx in rat DRG neurons, and it can attenuate dermatitis-associated barrier damages in <italic>Dermatophagoides farina</italic>- and <italic>oxazolone</italic>-induced mouse models of AD [<xref rid="B135-pharmaceuticals-11-00100" ref-type="bibr">135</xref>]. Recently, PAC-14028 went through multiple phase II clinical trials for determining its efficacy in relieving AD-associated pruritus (NCT02583022, NCT02052531, and NCT02565134), and an ongoing phase III trial of patients with AD is expected to be completed in late 2018 (NCT02965118). Although PAC-14028 shows a promising anti-itch effect in AD, a randomized clinical trial failed to find a symptomatic benefit of another TRPV1 antagonist, SB-705498, for histaminergic or non-histaminergic induced itch [<xref rid="B155-pharmaceuticals-11-00100" ref-type="bibr">155</xref>]. On the other hand, SB-705498 shows a promising inhibitory effect on heat-evoked pain and skin sensitization induced by capsaicin or UVB irradiation in humans [<xref rid="B156-pharmaceuticals-11-00100" ref-type="bibr">156</xref>], further suggesting distinct mechanisms might be involved in TRPV1-mediated pain and itch.</p></sec><sec id="sec4dot3-pharmaceuticals-11-00100"><title>4.3. TRPV3 Antagonists</title><p>Hydra Biosciences is the first company to develop small molecule TRPV3 antagonists and has identified a series of TRPV3 antagonists with IC<sub>50</sub> values in the range of 0.2&#x02013;1 &#x003bc;M [<xref rid="B157-pharmaceuticals-11-00100" ref-type="bibr">157</xref>]. These antagonists show good selectivity and lack adverse effects at doses of 200 mg/kg [<xref rid="B157-pharmaceuticals-11-00100" ref-type="bibr">157</xref>]. Glenmark Pharmaceuticals is another company dedicated to developing small molecule inhibitors of TRPV3 and has described several additional TRPV3 antagonists in patent applications. For instance, GRC 15,300 is the first TRPV3 inhibitor to enter clinical phase I and clinical phase II trials for treating neuropathic pain [<xref rid="B157-pharmaceuticals-11-00100" ref-type="bibr">157</xref>,<xref rid="B158-pharmaceuticals-11-00100" ref-type="bibr">158</xref>]. However, this research is discontinued and currently there are no known ongoing clinical trials employing TRPV3 antagonists [<xref rid="B158-pharmaceuticals-11-00100" ref-type="bibr">158</xref>].</p><p>Resolvins are endogenous anti-inflammatory molecules generated by &#x003c9;-3 lipid metabolism [<xref rid="B159-pharmaceuticals-11-00100" ref-type="bibr">159</xref>]. Interestingly, resolvin D1 (RvD1) and resolvin E1 (RvE1) could inhibit activities of multiple TRP channels [<xref rid="B160-pharmaceuticals-11-00100" ref-type="bibr">160</xref>]. Bang et al. demonstrated that 17R-RvD1 was a potent TRPV3 inhibitor [<xref rid="B137-pharmaceuticals-11-00100" ref-type="bibr">137</xref>]. The TRPV3-mediated Ca<sup>2+</sup> influxes elicited by 4 mM camphor were blocked by 17R-RvD1 with an IC<sub>50</sub> value of 398 nM [<xref rid="B137-pharmaceuticals-11-00100" ref-type="bibr">137</xref>]. More importantly, the other five TRP channels including TRPA1, TRPV1, TRPV2, TRPV4, and TRPM8 were not affected by 17R-RvD1. Thus, 17R-RvD1 represents a novel specific endogenous inhibitor of TRPV3. However, this TRPV3 antagonist has yet to be used to investigate itch.</p></sec><sec id="sec4dot4-pharmaceuticals-11-00100"><title>4.4. TRPV4 Antagonists</title><p>Everaerts et al. identified HC-067047, a small molecule antagonist of hTRPV4 that reversibly inhibited currents mediated by human, rat, and mouse TRPV4 orthologs with IC<sub>50</sub> values of 48 &#x000b1; 6 nM, 133 &#x000b1; 25 nM, and 17 &#x000b1; 3 nM, respectively [<xref rid="B138-pharmaceuticals-11-00100" ref-type="bibr">138</xref>]. In Ca<sup>2+</sup> imaging experiments, 1 &#x003bc;M HC-067047 completely inhibited mouse TRPV4 activated by heat, hypoosmotic solution, arachidonic acid, 4&#x003b1;-Phorbol 12,13-didecanoate (4&#x003b1;-PDD), 4&#x003b1;-phorbol 12,13-dihexanoate (4&#x003b1;-PDH), and GSK1016790A [<xref rid="B138-pharmaceuticals-11-00100" ref-type="bibr">138</xref>]. HC-067047 has a promising selectivity profile, lacking obvious effects on other ion channels except TRPM8 and hERG at submicromolar concentrations [<xref rid="B138-pharmaceuticals-11-00100" ref-type="bibr">138</xref>]. GSK2193874 is the most widely used specific antagonist of TRPV4. It inhibits human TRPV4 and rat TRPV4 with IC<sub>50</sub> values of 40 nM and 2 nM, respectively [<xref rid="B139-pharmaceuticals-11-00100" ref-type="bibr">139</xref>]. Importantly, it is selective against TRPV1, TRPA1, TRPC3, TRPC6, and TRPM8 (IC<sub>50</sub> &#x0003e; 25 &#x003bc;M) [<xref rid="B139-pharmaceuticals-11-00100" ref-type="bibr">139</xref>]. Both HC067047 and GSK2193874 have been used to investigate the role of TRPV4 in itch signaling. HC067047 significantly inhibits 5-HT-evoked scratching in mice [<xref rid="B27-pharmaceuticals-11-00100" ref-type="bibr">27</xref>]. Both HC067047 and GSK2193874 suppress spontaneous scratching in mouse models of acetone&#x02013;diethylether&#x02013;water (AEW)-induced dry skin and SADBE-induced ACD [<xref rid="B98-pharmaceuticals-11-00100" ref-type="bibr">98</xref>]. GSK205 is another small molecule TRPV4 blocker used for itch studies, although it also possesses an inhibitory effect on TRPA1 [<xref rid="B161-pharmaceuticals-11-00100" ref-type="bibr">161</xref>]. GSK205 is shown to inhibit itch elicited by localized skin warming as well as scratching responses induced by histaminergic (histamine, compound 48/80, ET-1), but not non-histaminergic (CQ) pruritogens [<xref rid="B28-pharmaceuticals-11-00100" ref-type="bibr">28</xref>].</p></sec><sec id="sec4dot5-pharmaceuticals-11-00100"><title>4.5. TRPC4 Antagonists</title><p>Although some small molecule TRPC4 antagonists are available, most of them have off-target effects. For instance, ML204 is identified as a novel TRPC4 antagonist with an IC<sub>50</sub> value of 0.96 &#x003bc;M [<xref rid="B140-pharmaceuticals-11-00100" ref-type="bibr">140</xref>]. However, ML204 also exhibits inhibitory effects on TRPC5 and TRPC6 channels at 10 &#x003bc;M [<xref rid="B140-pharmaceuticals-11-00100" ref-type="bibr">140</xref>]. Similarly, Zhu et al. identified M084 and its analogues as TRPC4 inhibitors with IC<sub>50</sub> values in the range of 4.1 &#x003bc;M to 11.0 &#x003bc;M [<xref rid="B162-pharmaceuticals-11-00100" ref-type="bibr">162</xref>]. Unfortunately, all these compounds also block TRPC5 with similar IC<sub>50</sub> values [<xref rid="B162-pharmaceuticals-11-00100" ref-type="bibr">162</xref>]. More recently, Just et al. reported a highly potent small molecule antagonist of TRPC4, HC-070, which inhibited hTRPC4 with an IC<sub>50</sub> value of 46.0 &#x000b1; 3.9 nM [<xref rid="B141-pharmaceuticals-11-00100" ref-type="bibr">141</xref>]. Although this compound is &#x0003e;400-fold selective over a wide range of molecular targets including ion channels, receptors, and kinases, it also inhibits hTRPC5 with an IC<sub>50</sub> value of 9.3 &#x000b1; 0.9 nM [<xref rid="B141-pharmaceuticals-11-00100" ref-type="bibr">141</xref>]. Selective TRPC4 blockers remain to be utilized for itch studies.</p></sec><sec id="sec4dot6-pharmaceuticals-11-00100"><title>4.6. TRPM8 Agonists</title><p>Specific TRPM8 activators are promising candidates for treating itch since the activation of TRPM8 by cooling or chemical agonists relieves itch [<xref rid="B125-pharmaceuticals-11-00100" ref-type="bibr">125</xref>,<xref rid="B163-pharmaceuticals-11-00100" ref-type="bibr">163</xref>]. Menthol and icilin are well-known and widely used compounds activating TRPM8 with EC<sub>50</sub> values of 10.4&#x02009;&#x003bc;M and 1.4&#x02009;&#x003bc;M, respectively [<xref rid="B145-pharmaceuticals-11-00100" ref-type="bibr">145</xref>,<xref rid="B146-pharmaceuticals-11-00100" ref-type="bibr">146</xref>]. Indeed, both menthol and icilin display excellent anti-itch effects. Menthol significantly reduces not only itch induced by mustard gas exposure but also lichen amyloidosis- and hydroxyethyl starch-evoked itch [<xref rid="B163-pharmaceuticals-11-00100" ref-type="bibr">163</xref>,<xref rid="B164-pharmaceuticals-11-00100" ref-type="bibr">164</xref>,<xref rid="B165-pharmaceuticals-11-00100" ref-type="bibr">165</xref>]. A topical icilin application relieves vulva pruritus originating from lichen sclerosus [<xref rid="B125-pharmaceuticals-11-00100" ref-type="bibr">125</xref>]. However, menthol can also activate TRPA1 and TRPV3, and icilin is also a potent TRPA1 activator [<xref rid="B166-pharmaceuticals-11-00100" ref-type="bibr">166</xref>,<xref rid="B167-pharmaceuticals-11-00100" ref-type="bibr">167</xref>].</p><p>Many other TRPM8 agonists have also been identified, including eucalyptol (1,8-cineol), WS-12, M8-Ag, CPS-369, and D-3263 [<xref rid="B114-pharmaceuticals-11-00100" ref-type="bibr">114</xref>,<xref rid="B168-pharmaceuticals-11-00100" ref-type="bibr">168</xref>,<xref rid="B169-pharmaceuticals-11-00100" ref-type="bibr">169</xref>]. Eucalyptol is the major ingredient in the essential oil of eucalyptus leaves. Eucalyptol-containing products are a widely used remedy for alleviating pain [<xref rid="B114-pharmaceuticals-11-00100" ref-type="bibr">114</xref>]. Eucalyptol is a TRPM8 agonist and can inhibit acid-induced visceral pain in a TRPM8-dependent manner [<xref rid="B114-pharmaceuticals-11-00100" ref-type="bibr">114</xref>,<xref rid="B170-pharmaceuticals-11-00100" ref-type="bibr">170</xref>]. However, eucalyptol activates TRPM8 with relatively low efficacy and potency (EC<sub>50</sub> = 3.4 &#x000b1; 0.4&#x02009;mM) and also inhibits TRPA1 [<xref rid="B142-pharmaceuticals-11-00100" ref-type="bibr">142</xref>,<xref rid="B143-pharmaceuticals-11-00100" ref-type="bibr">143</xref>]. M8-Ag is a potent TRPM8 agonist that activates TRPM8 with an EC<sub>50</sub> value of 45 nM [<xref rid="B144-pharmaceuticals-11-00100" ref-type="bibr">144</xref>]. However, M8-Ag also activates TRPA1 with an EC<sub>50</sub> of &#x0003e;4 &#x003bc;M [<xref rid="B144-pharmaceuticals-11-00100" ref-type="bibr">144</xref>]. WS-12 is another well-known and widely used TRPM8 agonist with an EC<sub>50</sub> of 193 nM [<xref rid="B145-pharmaceuticals-11-00100" ref-type="bibr">145</xref>,<xref rid="B146-pharmaceuticals-11-00100" ref-type="bibr">146</xref>]. WS-12 appears to be the most specific among the currently known TRPM8 agonists because it lacks actions on TRPV1, TRPV2, TRPV3, TRPV4, and TRPA1 at 1 mM [<xref rid="B113-pharmaceuticals-11-00100" ref-type="bibr">113</xref>]. The excellent potency and selectivity of WS-12 makes it a promising TRPM8 activator for treating itch.</p></sec></sec><sec id="sec5-pharmaceuticals-11-00100"><title>5. Conclusions and Future Perspectives</title><p>Persistent itch is debilitating and severely affects quality of life. Although antihistamines, corticosteroid creams, calcineurin inhibitors, and antidepressants have been widely used to treat itch, many of them are ineffective for chronic itch and exert numerous side effects. Novel and effective anti-itch drugs are urgently needed.</p><p>Molecular and cellular mechanisms underlying the regulation of itch signaling by TRP channels have not been completely understood. Accumulating evidence now identifies TRP channels as crucial players in mediating and modulating acute and chronic itch. The role of TRP channels in itch is becoming clearer and many TRP channel ligands have been developed, yet TRP channel ligands remain to be used clinically as anti-itch drugs. Off-target effects are a risk for TRP channel ligands given their broad expression and numerous biological functions. Thus, development should proceed with caution. Nevertheless, since recent stimulating studies have provided conclusive evidence that multiple TRP channels play critical roles in the initiation and maintenance of itch signaling, the development of new and selective drugs targeting TRP channels should hold promise for the treatment of chronic itch.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors wish to thank Tim Hibbert for the critical reading of the manuscript. </p></ack><notes><title>Author Contributions</title><p>Conceptualization, Z.X. and H.H.; Writing&#x02013;Original draft, Z.X. and H.H.; Writing&#x02013;Review and Editing, Z.X. and H.H.; Funding Acquisition, H.H.</p></notes><notes><title>Funding</title><p>This research was funded by grants from the National Institutes of Health (R01GM101218, R01DK103901, and R01AA027065) and the Department of Anesthesiology of Washington University School of Medicine.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><glossary><title>Abbreviation</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">TRP</td><td align="left" valign="middle" rowspan="1" colspan="1">transient receptor potential</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mrgpr</td><td align="left" valign="middle" rowspan="1" colspan="1">Mas-related G protein-coupled receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TSLP</td><td align="left" valign="middle" rowspan="1" colspan="1">thymic stromal lymphopoietin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TSLPR</td><td align="left" valign="middle" rowspan="1" colspan="1">thymic stromal lymphopoietin receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SLIGRL</td><td align="left" valign="middle" rowspan="1" colspan="1">peptide Ser-Leu-Ile-Gly-Arg-Leu</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BAM8-22</td><td align="left" valign="middle" rowspan="1" colspan="1">bovine adrenal medulla 8&#x02013;22 peptide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">5-HT</td><td align="left" valign="middle" rowspan="1" colspan="1">5-hydroxytryptamine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HTR7</td><td align="left" valign="middle" rowspan="1" colspan="1">5-hydroxytryptamine receptor 7</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGR5</td><td align="left" valign="middle" rowspan="1" colspan="1">G protein-coupled bile acid receptor Gpbar1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PLC</td><td align="left" valign="middle" rowspan="1" colspan="1">phospholipase C</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H1R</td><td align="left" valign="middle" rowspan="1" colspan="1">histamine receptor 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H2R</td><td align="left" valign="middle" rowspan="1" colspan="1">histamine receptor 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H3R</td><td align="left" valign="middle" rowspan="1" colspan="1">histamine receptor 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">H4R</td><td align="left" valign="middle" rowspan="1" colspan="1">histamine receptor 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SADBE</td><td align="left" valign="middle" rowspan="1" colspan="1">squaric acid dibutylester</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LPA</td><td align="left" valign="middle" rowspan="1" colspan="1">lysophosphatidic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL-31</td><td align="left" valign="middle" rowspan="1" colspan="1">interleukin-31</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AEW</td><td align="left" valign="middle" rowspan="1" colspan="1">acetone&#x02013;diethylether&#x02013;water</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CQ</td><td align="left" valign="middle" rowspan="1" colspan="1">chloroquine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4-HNE</td><td align="left" valign="middle" rowspan="1" colspan="1">4-hydroxynonenal</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">S1P</td><td align="left" valign="middle" rowspan="1" colspan="1">sphingosine 1-phosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">S1PR3</td><td align="left" valign="middle" rowspan="1" colspan="1">sphingosine 1-phosphate receptor 3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OS</td><td align="left" valign="middle" rowspan="1" colspan="1">Olmsted syndrome</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GPCR</td><td align="left" valign="middle" rowspan="1" colspan="1">G protein-coupled receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AD</td><td align="left" valign="middle" rowspan="1" colspan="1">atopic dermatitis </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">KO</td><td align="left" valign="middle" rowspan="1" colspan="1">knockout</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PKC</td><td align="left" valign="middle" rowspan="1" colspan="1">protein kinase C</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GRP</td><td align="left" valign="middle" rowspan="1" colspan="1">gastrin-releasing peptide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL7R</td><td align="left" valign="middle" rowspan="1" colspan="1">interleukin-7 receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CHS</td><td align="left" valign="middle" rowspan="1" colspan="1">contact hypersensitivity</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ACD</td><td align="left" valign="middle" rowspan="1" colspan="1">allergic contact dermatitis</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LTB<sub>4</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">leukotriene B<sub>4</sub></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">2-APB</td><td align="left" valign="middle" rowspan="1" colspan="1">2-aminoethoxydiphenyl borate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CIP</td><td align="left" valign="middle" rowspan="1" colspan="1">chronic idiopathic pruritus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ET-1</td><td align="left" valign="middle" rowspan="1" colspan="1">endothelin-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SSRIs</td><td align="left" valign="middle" rowspan="1" colspan="1">selective serotonin reuptake inhibitors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AYP</td><td align="left" valign="middle" rowspan="1" colspan="1">AYPGKF-NH<sub>2</sub></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DNCB</td><td align="left" valign="middle" rowspan="1" colspan="1">dinitrochlorobenzene</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CGRP</td><td align="left" valign="middle" rowspan="1" colspan="1">calcitonin gene-related peptide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RvD1</td><td align="left" valign="middle" rowspan="1" colspan="1">resolvin D1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RvE1</td><td align="left" valign="middle" rowspan="1" colspan="1">resolvin E1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4&#x003b1;-PDD</td><td align="left" valign="middle" rowspan="1" colspan="1">4&#x003b1;-Phorbol 12,13-didecanoate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">4&#x003b1;-PDH</td><td align="left" valign="middle" rowspan="1" colspan="1">4&#x003b1;-phorbol 12,13-dihexanoate</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-11-00100"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paus</surname><given-names>R.</given-names></name><name><surname>Schmelz</surname><given-names>M.</given-names></name><name><surname>Biro</surname><given-names>T.</given-names></name><name><surname>Steinhoff</surname><given-names>M.</given-names></name></person-group><article-title>Frontiers in pruritus research: Scratching the brain for more effective itch therapy</article-title><source>J. Clin. Investig.</source><year>2006</year><volume>116</volume><fpage>1174</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1172/JCI28553</pub-id><?supplied-pmid 16670758?><pub-id pub-id-type="pmid">16670758</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-11-00100"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>T.</given-names></name><name><surname>Carstens</surname><given-names>E.</given-names></name></person-group><article-title>Neural processing of itch</article-title><source>Neuroscience</source><year>2013</year><volume>250</volume><fpage>697</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.07.035</pub-id><?supplied-pmid 23891755?><pub-id pub-id-type="pmid">23891755</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-11-00100"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Yosipovitch</surname><given-names>G.</given-names></name></person-group><article-title>New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma</article-title><source>Int. J. Dermatol.</source><year>2010</year><volume>49</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1111/j.1365-4632.2009.04249.x</pub-id><?supplied-pmid 20465602?><pub-id pub-id-type="pmid">20465602</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-11-00100"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boguniewicz</surname><given-names>M.</given-names></name><name><surname>Leung</surname><given-names>D.Y.</given-names></name></person-group><article-title>Atopic dermatitis: A disease of altered skin barrier and immune dysregulation</article-title><source>Immunol. Rev.</source><year>2011</year><volume>242</volume><fpage>233</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2011.01027.x</pub-id><?supplied-pmid 21682749?><pub-id pub-id-type="pmid">21682749</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-11-00100"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunchorntavakul</surname><given-names>C.</given-names></name><name><surname>Reddy</surname><given-names>K.R.</given-names></name></person-group><article-title>Pruritus in chronic cholestatic liver disease</article-title><source>Clin. Liver Dis.</source><year>2012</year><volume>16</volume><fpage>331</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2012.03.010</pub-id><?supplied-pmid 22541702?><pub-id pub-id-type="pmid">22541702</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-11-00100"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikoma</surname><given-names>A.</given-names></name><name><surname>Steinhoff</surname><given-names>M.</given-names></name><name><surname>Stander</surname><given-names>S.</given-names></name><name><surname>Yosipovitch</surname><given-names>G.</given-names></name><name><surname>Schmelz</surname><given-names>M.</given-names></name></person-group><article-title>The neurobiology of itch</article-title><source>Nat. Rev. Neurosci.</source><year>2006</year><volume>7</volume><fpage>535</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1038/nrn1950</pub-id><?supplied-pmid 16791143?><pub-id pub-id-type="pmid">16791143</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-11-00100"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montell</surname><given-names>C.</given-names></name><name><surname>Birnbaumer</surname><given-names>L.</given-names></name><name><surname>Flockerzi</surname><given-names>V.</given-names></name></person-group><article-title>The TRP channels, a remarkably functional family</article-title><source>Cell</source><year>2002</year><volume>108</volume><fpage>595</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00670-0</pub-id><pub-id pub-id-type="pmid">11893331</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-11-00100"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkatachalam</surname><given-names>K.</given-names></name><name><surname>Montell</surname><given-names>C.</given-names></name></person-group><article-title>TRP channels</article-title><source>Annu. Rev. Biochem.</source><year>2007</year><volume>76</volume><fpage>387</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.75.103004.142819</pub-id><?supplied-pmid 17579562?><pub-id pub-id-type="pmid">17579562</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-11-00100"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>Z.</given-names></name><name><surname>Rhyu</surname><given-names>M.R.</given-names></name><name><surname>Phan</surname><given-names>T.H.</given-names></name><name><surname>Mummalaneni</surname><given-names>S.</given-names></name><name><surname>Murthy</surname><given-names>K.S.</given-names></name><name><surname>Grider</surname><given-names>J.R.</given-names></name><name><surname>DeSimone</surname><given-names>J.A.</given-names></name><name><surname>Lyall</surname><given-names>V.</given-names></name></person-group><article-title>TRPM5-dependent amiloride- and benzamil-insensitive NaCl chorda tympani taste nerve response</article-title><source>Am. J. Physiol. Gastrointest. Liver Physiol.</source><year>2013</year><volume>305</volume><fpage>G106</fpage><lpage>G117</lpage><pub-id pub-id-type="doi">10.1152/ajpgi.00053.2013</pub-id><?supplied-pmid 23639808?><pub-id pub-id-type="pmid">23639808</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-11-00100"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>J.</given-names></name></person-group><article-title>Molecular mechanism of TRP channels</article-title><source>Compr. Physiol.</source><year>2013</year><volume>3</volume><fpage>221</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1002/cphy.c120001</pub-id><?supplied-pmid 23720286?><pub-id pub-id-type="pmid">23720286</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-11-00100"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatzigeorgiou</surname><given-names>M.</given-names></name><name><surname>Yoo</surname><given-names>S.</given-names></name><name><surname>Watson</surname><given-names>J.D.</given-names></name><name><surname>Lee</surname><given-names>W.H.</given-names></name><name><surname>Spencer</surname><given-names>W.C.</given-names></name><name><surname>Kindt</surname><given-names>K.S.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name><name><surname>Miller</surname><given-names>D.M.</given-names><suffix>3rd</suffix></name><name><surname>Treinin</surname><given-names>M.</given-names></name><name><surname>Driscoll</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Specific roles for DEG/ENaC and TRP channels in touch and thermosensation in C. elegans nociceptors</article-title><source>Nat. Neurosci.</source><year>2010</year><volume>13</volume><fpage>861</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1038/nn.2581</pub-id><?supplied-pmid 20512132?><pub-id pub-id-type="pmid">20512132</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-11-00100"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L.J.</given-names></name><name><surname>Sweet</surname><given-names>T.B.</given-names></name><name><surname>Clapham</surname><given-names>D.E.</given-names></name></person-group><article-title>International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family</article-title><source>Pharmacol. Rev.</source><year>2010</year><volume>62</volume><fpage>381</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1124/pr.110.002725</pub-id><?supplied-pmid 20716668?><pub-id pub-id-type="pmid">20716668</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-11-00100"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinhoff</surname><given-names>M.</given-names></name><name><surname>Biro</surname><given-names>T.</given-names></name></person-group><article-title>A TR(I)P to pruritus research: Role of TRPV3 in inflammation and itch</article-title><source>J. Investig. Dermatol.</source><year>2009</year><volume>129</volume><fpage>531</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1038/jid.2008.440</pub-id><?supplied-pmid 19209153?><pub-id pub-id-type="pmid">19209153</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-11-00100"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>C.</given-names></name><name><surname>Gupta</surname><given-names>R.</given-names></name><name><surname>Jordt</surname><given-names>S.E.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Liedtke</surname><given-names>W.B.</given-names></name></person-group><article-title>Regulation of Pain and Itch by TRP Channels</article-title><source>Neurosci. Bull.</source><year>2018</year><volume>34</volume><fpage>120</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1007/s12264-017-0200-8</pub-id><?supplied-pmid 29282613?><pub-id pub-id-type="pmid">29282613</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-11-00100"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>S.B.</given-names></name><name><surname>Koltzenburg</surname><given-names>M.</given-names></name></person-group><article-title>Itching for an explanation</article-title><source>Trends Neurosci.</source><year>1992</year><volume>15</volume><fpage>497</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/0166-2236(92)90102-E</pub-id><pub-id pub-id-type="pmid">1282750</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-11-00100"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>L.</given-names></name><name><surname>Wright</surname><given-names>E.</given-names></name><name><surname>McMahon</surname><given-names>S.B.</given-names></name></person-group><article-title>A comparison of the effects of noxious and innocuous counterstimuli on experimentally induced itch and pain</article-title><source>Pain</source><year>1996</year><volume>64</volume><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(95)00080-1</pub-id><pub-id pub-id-type="pmid">8867255</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-11-00100"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.Y.</given-names></name><name><surname>Liu</surname><given-names>Z.C.</given-names></name><name><surname>Sun</surname><given-names>Y.G.</given-names></name><name><surname>Ross</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Tsai</surname><given-names>F.F.</given-names></name><name><surname>Li</surname><given-names>Q.F.</given-names></name><name><surname>Jeffry</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>J.Y.</given-names></name><name><surname>Loh</surname><given-names>H.H.</given-names></name><etal/></person-group><article-title>Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids</article-title><source>Cell</source><year>2011</year><volume>147</volume><fpage>447</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.08.043</pub-id><?supplied-pmid 22000021?><pub-id pub-id-type="pmid">22000021</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-11-00100"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y.G.</given-names></name><name><surname>Zhao</surname><given-names>Z.Q.</given-names></name><name><surname>Meng</surname><given-names>X.L.</given-names></name><name><surname>Yin</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>X.Y.</given-names></name><name><surname>Chen</surname><given-names>Z.F.</given-names></name></person-group><article-title>Cellular basis of itch sensation</article-title><source>Science</source><year>2009</year><volume>325</volume><fpage>1531</fpage><lpage>1534</lpage><pub-id pub-id-type="doi">10.1126/science.1174868</pub-id><?supplied-pmid 19661382?><pub-id pub-id-type="pmid">19661382</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-11-00100"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name></person-group><article-title>Peripheral and Central Mechanisms of Itch</article-title><source>Neuron</source><year>2018</year><volume>98</volume><fpage>482</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.03.023</pub-id><?supplied-pmid 29723501?><pub-id pub-id-type="pmid">29723501</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-11-00100"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaMotte</surname><given-names>R.H.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Ringkamp</surname><given-names>M.</given-names></name></person-group><article-title>Sensory neurons and circuits mediating itch</article-title><source>Nat. Rev. Neurosci.</source><year>2014</year><volume>15</volume><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1038/nrn3641</pub-id><?supplied-pmid 24356071?><pub-id pub-id-type="pmid">24356071</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-11-00100"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Weng</surname><given-names>H.J.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Tang</surname><given-names>Z.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Nie</surname><given-names>H.</given-names></name><name><surname>Qu</surname><given-names>L.</given-names></name><name><surname>Patel</surname><given-names>K.N.</given-names></name><etal/></person-group><article-title>A subpopulation of nociceptors specifically linked to itch</article-title><source>Nat. Neurosci.</source><year>2013</year><volume>16</volume><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1038/nn.3289</pub-id><?supplied-pmid 23263443?><pub-id pub-id-type="pmid">23263443</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-11-00100"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Walters</surname><given-names>E.T.</given-names></name><name><surname>Hu</surname><given-names>H.</given-names></name></person-group><article-title>Molecular and cellular mechanisms that initiate pain and itch</article-title><source>Cell. Mol. Life Sci. CMLS</source><year>2015</year><volume>72</volume><fpage>3201</fpage><lpage>3223</lpage><pub-id pub-id-type="doi">10.1007/s00018-015-1904-4</pub-id><?supplied-pmid 25894692?><pub-id pub-id-type="pmid">25894692</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-11-00100"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galli</surname><given-names>S.J.</given-names></name><name><surname>Nakae</surname><given-names>S.</given-names></name><name><surname>Tsai</surname><given-names>M.</given-names></name></person-group><article-title>Mast cells in the development of adaptive immune responses</article-title><source>Nat. Immunol.</source><year>2005</year><volume>6</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1038/ni1158</pub-id><?supplied-pmid 15662442?><pub-id pub-id-type="pmid">15662442</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-11-00100"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Werfel</surname><given-names>T.</given-names></name><name><surname>Allam</surname><given-names>J.P.</given-names></name><name><surname>Biedermann</surname><given-names>T.</given-names></name><name><surname>Eyerich</surname><given-names>K.</given-names></name><name><surname>Gilles</surname><given-names>S.</given-names></name><name><surname>Guttman-Yassky</surname><given-names>E.</given-names></name><name><surname>Hoetzenecker</surname><given-names>W.</given-names></name><name><surname>Knol</surname><given-names>E.</given-names></name><name><surname>Simon</surname><given-names>H.U.</given-names></name><name><surname>Wollenberg</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cellular and molecular immunologic mechanisms in patients with atopic dermatitis</article-title><source>J. Allergy Clin. Immunol.</source><year>2016</year><volume>138</volume><fpage>336</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2016.06.010</pub-id><?supplied-pmid 27497276?><pub-id pub-id-type="pmid">27497276</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-11-00100"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feld</surname><given-names>M.</given-names></name><name><surname>Garcia</surname><given-names>R.</given-names></name><name><surname>Buddenkotte</surname><given-names>J.</given-names></name><name><surname>Katayama</surname><given-names>S.</given-names></name><name><surname>Lewis</surname><given-names>K.</given-names></name><name><surname>Muirhead</surname><given-names>G.</given-names></name><name><surname>Hevezi</surname><given-names>P.</given-names></name><name><surname>Plesser</surname><given-names>K.</given-names></name><name><surname>Schrumpf</surname><given-names>H.</given-names></name><name><surname>Krjutskov</surname><given-names>K.</given-names></name><etal/></person-group><article-title>The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves</article-title><source>J. Allergy Clin. Immunol.</source><year>2016</year><volume>138</volume><fpage>500</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2016.02.020</pub-id><?supplied-pmid 27212086?><pub-id pub-id-type="pmid">27212086</pub-id></element-citation></ref><ref id="B26-pharmaceuticals-11-00100"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cevikbas</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Akiyama</surname><given-names>T.</given-names></name><name><surname>Kempkes</surname><given-names>C.</given-names></name><name><surname>Savinko</surname><given-names>T.</given-names></name><name><surname>Antal</surname><given-names>A.</given-names></name><name><surname>Kukova</surname><given-names>G.</given-names></name><name><surname>Buhl</surname><given-names>T.</given-names></name><name><surname>Ikoma</surname><given-names>A.</given-names></name><name><surname>Buddenkotte</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1</article-title><source>J. Allergy Clin. Immunol.</source><year>2014</year><volume>133</volume><fpage>448</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2013.10.048</pub-id><?supplied-pmid 24373353?><pub-id pub-id-type="pmid">24373353</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-11-00100"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>T.</given-names></name><name><surname>Ivanov</surname><given-names>M.</given-names></name><name><surname>Nagamine</surname><given-names>M.</given-names></name><name><surname>Davoodi</surname><given-names>A.</given-names></name><name><surname>Carstens</surname><given-names>M.I.</given-names></name><name><surname>Ikoma</surname><given-names>A.</given-names></name><name><surname>Cevikbas</surname><given-names>F.</given-names></name><name><surname>Kempkes</surname><given-names>C.</given-names></name><name><surname>Buddenkotte</surname><given-names>J.</given-names></name><name><surname>Steinhoff</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Involvement of TRPV4 in Serotonin-Evoked Scratching</article-title><source>J. Investig. Dermatol.</source><year>2016</year><volume>136</volume><fpage>154</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1038/JID.2015.388</pub-id><?supplied-pmid 26763435?><pub-id pub-id-type="pmid">26763435</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-11-00100"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Fang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>J.Y.</given-names></name><name><surname>MacLeod</surname><given-names>A.S.</given-names></name><name><surname>Hall</surname><given-names>R.P.</given-names></name><name><surname>Liedtke</surname><given-names>W.B.</given-names></name></person-group><article-title>Transient Receptor Potential Vanilloid 4 Ion Channel Functions as a Pruriceptor in Epidermal Keratinocytes to Evoke Histaminergic Itch</article-title><source>J. Boil. Chem.</source><year>2016</year><volume>291</volume><fpage>10252</fpage><lpage>10262</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.716464</pub-id><?supplied-pmid 26961876?><pub-id pub-id-type="pmid">26961876</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-11-00100"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Barry</surname><given-names>D.M.</given-names></name><name><surname>Liu</surname><given-names>X.Y.</given-names></name><name><surname>Yin</surname><given-names>S.</given-names></name><name><surname>Munanairi</surname><given-names>A.</given-names></name><name><surname>Meng</surname><given-names>Q.T.</given-names></name><name><surname>Cheng</surname><given-names>W.</given-names></name><name><surname>Mo</surname><given-names>P.</given-names></name><name><surname>Wan</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>S.B.</given-names></name><etal/></person-group><article-title>Facilitation of TRPV4 by TRPV1 is required for itch transmission in some sensory neuron populations</article-title><source>Sci. Signal.</source><year>2016</year><volume>9</volume><fpage>ra71</fpage><pub-id pub-id-type="doi">10.1126/scisignal.aaf1047</pub-id><?supplied-pmid 27436359?><pub-id pub-id-type="pmid">27436359</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-11-00100"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Mack</surname><given-names>M.R.</given-names></name><name><surname>Dryn</surname><given-names>D.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Oetjen</surname><given-names>L.K.</given-names></name><name><surname>Zholos</surname><given-names>A.V.</given-names></name><name><surname>Mei</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Sensory TRP channels contribute differentially to skin inflammation and persistent itch</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>980</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-01056-8</pub-id><?supplied-pmid 29081531?><pub-id pub-id-type="pmid">29081531</pub-id></element-citation></ref><ref id="B31-pharmaceuticals-11-00100"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kittaka</surname><given-names>H.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name></person-group><article-title>The molecular and cellular mechanisms of itch and the involvement of TRP channels in the peripheral sensory nervous system and skin</article-title><source>Allergol. Int. Off. J. Jpn. Soc. Allergol.</source><year>2017</year><volume>66</volume><fpage>22</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.alit.2016.10.003</pub-id><?supplied-pmid 28012781?><pub-id pub-id-type="pmid">28012781</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-11-00100"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caterina</surname><given-names>M.J.</given-names></name><name><surname>Pang</surname><given-names>Z.</given-names></name></person-group><article-title>TRP Channels in Skin Biology and Pathophysiology</article-title><source>Pharmaceuticals</source><year>2016</year><volume>9</volume><pub-id pub-id-type="doi">10.3390/ph9040077</pub-id><?supplied-pmid 27983625?><pub-id pub-id-type="pmid">27983625</pub-id></element-citation></ref><ref id="B33-pharmaceuticals-11-00100"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name></person-group><article-title>Trp channels and itch</article-title><source>Semin. Immunopathol.</source><year>2016</year><volume>38</volume><fpage>293</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1007/s00281-015-0530-4</pub-id><?supplied-pmid 26385480?><pub-id pub-id-type="pmid">26385480</pub-id></element-citation></ref><ref id="B34-pharmaceuticals-11-00100"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster</surname><given-names>S.L.</given-names></name><name><surname>Seehus</surname><given-names>C.R.</given-names></name><name><surname>Woolf</surname><given-names>C.J.</given-names></name><name><surname>Talbot</surname><given-names>S.</given-names></name></person-group><article-title>Sense and Immunity: Context-Dependent Neuro-Immune Interplay</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1463</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01463</pub-id><?supplied-pmid 29163530?><pub-id pub-id-type="pmid">29163530</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-11-00100"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zygmunt</surname><given-names>P.M.</given-names></name><name><surname>Hogestatt</surname><given-names>E.D.</given-names></name></person-group><article-title>Trpa1</article-title><source>Handb. Exp. Pharmacol.</source><year>2014</year><volume>222</volume><fpage>583</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-54215-2_23</pub-id><?supplied-pmid 24756722?><pub-id pub-id-type="pmid">24756722</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-11-00100"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Story</surname><given-names>G.M.</given-names></name><name><surname>Peier</surname><given-names>A.M.</given-names></name><name><surname>Reeve</surname><given-names>A.J.</given-names></name><name><surname>Eid</surname><given-names>S.R.</given-names></name><name><surname>Mosbacher</surname><given-names>J.</given-names></name><name><surname>Hricik</surname><given-names>T.R.</given-names></name><name><surname>Earley</surname><given-names>T.J.</given-names></name><name><surname>Hergarden</surname><given-names>A.C.</given-names></name><name><surname>Andersson</surname><given-names>D.A.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name><etal/></person-group><article-title>ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures</article-title><source>Cell</source><year>2003</year><volume>112</volume><fpage>819</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(03)00158-2</pub-id><pub-id pub-id-type="pmid">12654248</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-11-00100"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordt</surname><given-names>S.E.</given-names></name><name><surname>Bautista</surname><given-names>D.M.</given-names></name><name><surname>Chuang</surname><given-names>H.H.</given-names></name><name><surname>McKemy</surname><given-names>D.D.</given-names></name><name><surname>Zygmunt</surname><given-names>P.M.</given-names></name><name><surname>Hogestatt</surname><given-names>E.D.</given-names></name><name><surname>Meng</surname><given-names>I.D.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name></person-group><article-title>Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1</article-title><source>Nature</source><year>2004</year><volume>427</volume><fpage>260</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1038/nature02282</pub-id><?supplied-pmid 14712238?><pub-id pub-id-type="pmid">14712238</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-11-00100"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atoyan</surname><given-names>R.</given-names></name><name><surname>Shander</surname><given-names>D.</given-names></name><name><surname>Botchkareva</surname><given-names>N.V.</given-names></name></person-group><article-title>Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin</article-title><source>J. Investig. Dermatol.</source><year>2009</year><volume>129</volume><fpage>2312</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1038/jid.2009.58</pub-id><?supplied-pmid 19282836?><pub-id pub-id-type="pmid">19282836</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-11-00100"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takaya</surname><given-names>J.</given-names></name><name><surname>Mio</surname><given-names>K.</given-names></name><name><surname>Shiraishi</surname><given-names>T.</given-names></name><name><surname>Kurokawa</surname><given-names>T.</given-names></name><name><surname>Otsuka</surname><given-names>S.</given-names></name><name><surname>Mori</surname><given-names>Y.</given-names></name><name><surname>Uesugi</surname><given-names>M.</given-names></name></person-group><article-title>A Potent and Site-Selective Agonist of TRPA1</article-title><source>J. Am. Chem. Soc.</source><year>2015</year><volume>137</volume><fpage>15859</fpage><lpage>15864</lpage><pub-id pub-id-type="doi">10.1021/jacs.5b10162</pub-id><?supplied-pmid 26630251?><pub-id pub-id-type="pmid">26630251</pub-id></element-citation></ref><ref id="B40-pharmaceuticals-11-00100"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alpizar</surname><given-names>Y.A.</given-names></name><name><surname>Gees</surname><given-names>M.</given-names></name><name><surname>Sanchez</surname><given-names>A.</given-names></name><name><surname>Apetrei</surname><given-names>A.</given-names></name><name><surname>Voets</surname><given-names>T.</given-names></name><name><surname>Nilius</surname><given-names>B.</given-names></name><name><surname>Talavera</surname><given-names>K.</given-names></name></person-group><article-title>Bimodal effects of cinnamaldehyde and camphor on mouse TRPA1</article-title><source>Pflugers Arch. Eur. J. Physiol.</source><year>2013</year><volume>465</volume><fpage>853</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1007/s00424-012-1204-x</pub-id><?supplied-pmid 23271453?><pub-id pub-id-type="pmid">23271453</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-11-00100"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macpherson</surname><given-names>L.J.</given-names></name><name><surname>Geierstanger</surname><given-names>B.H.</given-names></name><name><surname>Viswanath</surname><given-names>V.</given-names></name><name><surname>Bandell</surname><given-names>M.</given-names></name><name><surname>Eid</surname><given-names>S.R.</given-names></name><name><surname>Hwang</surname><given-names>S.</given-names></name><name><surname>Patapoutian</surname><given-names>A.</given-names></name></person-group><article-title>The pungency of garlic: Activation of TRPA1 and TRPV1 in response to allicin</article-title><source>Curr. Boil.</source><year>2005</year><volume>15</volume><fpage>929</fpage><lpage>934</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2005.04.018</pub-id><?supplied-pmid 15916949?><pub-id pub-id-type="pmid">15916949</pub-id></element-citation></ref><ref id="B42-pharmaceuticals-11-00100"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawada</surname><given-names>Y.</given-names></name><name><surname>Hosokawa</surname><given-names>H.</given-names></name><name><surname>Matsumura</surname><given-names>K.</given-names></name><name><surname>Kobayashi</surname><given-names>S.</given-names></name></person-group><article-title>Activation of transient receptor potential ankyrin 1 by hydrogen peroxide</article-title><source>Eur. J. Neurosci.</source><year>2008</year><volume>27</volume><fpage>1131</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2008.06093.x</pub-id><?supplied-pmid 18364033?><pub-id pub-id-type="pmid">18364033</pub-id></element-citation></ref><ref id="B43-pharmaceuticals-11-00100"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trevisani</surname><given-names>M.</given-names></name><name><surname>Siemens</surname><given-names>J.</given-names></name><name><surname>Materazzi</surname><given-names>S.</given-names></name><name><surname>Bautista</surname><given-names>D.M.</given-names></name><name><surname>Nassini</surname><given-names>R.</given-names></name><name><surname>Campi</surname><given-names>B.</given-names></name><name><surname>Imamachi</surname><given-names>N.</given-names></name><name><surname>Andre</surname><given-names>E.</given-names></name><name><surname>Patacchini</surname><given-names>R.</given-names></name><name><surname>Cottrell</surname><given-names>G.S.</given-names></name><etal/></person-group><article-title>4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>13519</fpage><lpage>13524</lpage><pub-id pub-id-type="doi">10.1073/pnas.0705923104</pub-id><?supplied-pmid 17684094?><pub-id pub-id-type="pmid">17684094</pub-id></element-citation></ref><ref id="B44-pharmaceuticals-11-00100"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Bandell</surname><given-names>M.</given-names></name><name><surname>Petrus</surname><given-names>M.J.</given-names></name><name><surname>Zhu</surname><given-names>M.X.</given-names></name><name><surname>Patapoutian</surname><given-names>A.</given-names></name></person-group><article-title>Zinc activates damage-sensing TRPA1 ion channels</article-title><source>Nat. Chem. Boil.</source><year>2009</year><volume>5</volume><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/nchembio.146</pub-id><?supplied-pmid 19202543?><pub-id pub-id-type="pmid">19202543</pub-id></element-citation></ref><ref id="B45-pharmaceuticals-11-00100"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieu</surname><given-names>T.</given-names></name><name><surname>Jayaweera</surname><given-names>G.</given-names></name><name><surname>Zhao</surname><given-names>P.</given-names></name><name><surname>Poole</surname><given-names>D.P.</given-names></name><name><surname>Jensen</surname><given-names>D.</given-names></name><name><surname>Grace</surname><given-names>M.</given-names></name><name><surname>McIntyre</surname><given-names>P.</given-names></name><name><surname>Bron</surname><given-names>R.</given-names></name><name><surname>Wilson</surname><given-names>Y.M.</given-names></name><name><surname>Krappitz</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice</article-title><source>Gastroenterology</source><year>2014</year><volume>147</volume><fpage>1417</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2014.08.042</pub-id><?supplied-pmid 25194674?><pub-id pub-id-type="pmid">25194674</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-11-00100"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Tang</surname><given-names>Z.</given-names></name><name><surname>Surdenikova</surname><given-names>L.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Patel</surname><given-names>K.N.</given-names></name><name><surname>Kim</surname><given-names>A.</given-names></name><name><surname>Ru</surname><given-names>F.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Weng</surname><given-names>H.J.</given-names></name><name><surname>Geng</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus</article-title><source>Cell</source><year>2009</year><volume>139</volume><fpage>1353</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.11.034</pub-id><?supplied-pmid 20004959?><pub-id pub-id-type="pmid">20004959</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-11-00100"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>S.R.</given-names></name><name><surname>The</surname><given-names>L.</given-names></name><name><surname>Batia</surname><given-names>L.M.</given-names></name><name><surname>Beattie</surname><given-names>K.</given-names></name><name><surname>Katibah</surname><given-names>G.E.</given-names></name><name><surname>McClain</surname><given-names>S.P.</given-names></name><name><surname>Pellegrino</surname><given-names>M.</given-names></name><name><surname>Estandian</surname><given-names>D.M.</given-names></name><name><surname>Bautista</surname><given-names>D.M.</given-names></name></person-group><article-title>The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch</article-title><source>Cell</source><year>2013</year><volume>155</volume><fpage>285</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.08.057</pub-id><?supplied-pmid 24094650?><pub-id pub-id-type="pmid">24094650</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-11-00100"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>S.R.</given-names></name><name><surname>Gerhold</surname><given-names>K.A.</given-names></name><name><surname>Bifolck-Fisher</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>Q.</given-names></name><name><surname>Patel</surname><given-names>K.N.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Bautista</surname><given-names>D.M.</given-names></name></person-group><article-title>TRPA1 is required for histamine-independent, Mas-related G protein-coupled receptor-mediated itch</article-title><source>Nat. Neurosci.</source><year>2011</year><volume>14</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/nn.2789</pub-id><?supplied-pmid 21460831?><pub-id pub-id-type="pmid">21460831</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-11-00100"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ru</surname><given-names>F.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Jurcakova</surname><given-names>D.</given-names></name><name><surname>Herbstsomer</surname><given-names>R.A.</given-names></name><name><surname>Meixong</surname><given-names>J.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Undem</surname><given-names>B.J.</given-names></name></person-group><article-title>Mechanisms of pruritogen-induced activation of itch nerves in isolated mouse skin</article-title><source>J. Physiol.</source><year>2017</year><volume>595</volume><fpage>3651</fpage><lpage>3666</lpage><pub-id pub-id-type="doi">10.1113/JP273795</pub-id><?supplied-pmid 28217875?><pub-id pub-id-type="pmid">28217875</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-11-00100"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>M.L.</given-names></name><name><surname>Joesting</surname><given-names>J.J.</given-names></name><name><surname>Lawson</surname><given-names>M.A.</given-names></name><name><surname>Chiu</surname><given-names>G.S.</given-names></name><name><surname>Blevins</surname><given-names>N.A.</given-names></name><name><surname>Kwakwa</surname><given-names>K.A.</given-names></name><name><surname>Freund</surname><given-names>G.G.</given-names></name></person-group><article-title>The saturated fatty acid, palmitic acid, induces anxiety-like behavior in mice</article-title><source>Metab. Clin. Exp.</source><year>2014</year><volume>63</volume><fpage>1131</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1016/j.metabol.2014.06.002</pub-id><?supplied-pmid 25016520?><pub-id pub-id-type="pmid">25016520</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-11-00100"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soga</surname><given-names>F.</given-names></name><name><surname>Katoh</surname><given-names>N.</given-names></name><name><surname>Inoue</surname><given-names>T.</given-names></name><name><surname>Kishimoto</surname><given-names>S.</given-names></name></person-group><article-title>Serotonin activates human monocytes and prevents apoptosis</article-title><source>J. Investig. Dermatol.</source><year>2007</year><volume>127</volume><fpage>1947</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5700824</pub-id><?supplied-pmid 17429435?><pub-id pub-id-type="pmid">17429435</pub-id></element-citation></ref><ref id="B52-pharmaceuticals-11-00100"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>T.</given-names></name><name><surname>McClain</surname><given-names>S.P.</given-names></name><name><surname>Batia</surname><given-names>L.M.</given-names></name><name><surname>Pellegrino</surname><given-names>M.</given-names></name><name><surname>Wilson</surname><given-names>S.R.</given-names></name><name><surname>Kienzler</surname><given-names>M.A.</given-names></name><name><surname>Lyman</surname><given-names>K.</given-names></name><name><surname>Olsen</surname><given-names>A.S.</given-names></name><name><surname>Wong</surname><given-names>J.F.</given-names></name><name><surname>Stucky</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>HTR7 Mediates Serotonergic Acute and Chronic Itch</article-title><source>Neuron</source><year>2015</year><volume>87</volume><fpage>124</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2015.05.044</pub-id><?supplied-pmid 26074006?><pub-id pub-id-type="pmid">26074006</pub-id></element-citation></ref><ref id="B53-pharmaceuticals-11-00100"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassari</surname><given-names>R.</given-names></name><name><surname>Koea</surname><given-names>J.B.</given-names></name></person-group><article-title>Jaundice associated pruritis: A review of pathophysiology and treatment</article-title><source>World J. Gastroenterol.</source><year>2015</year><volume>21</volume><fpage>1404</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i5.1404</pub-id><?supplied-pmid 25663760?><pub-id pub-id-type="pmid">25663760</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-11-00100"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mela</surname><given-names>M.</given-names></name><name><surname>Mancuso</surname><given-names>A.</given-names></name><name><surname>Burroughs</surname><given-names>A.K.</given-names></name></person-group><article-title>Review article: Pruritus in cholestatic and other liver diseases</article-title><source>Aliment. Pharmacol. Ther.</source><year>2003</year><volume>17</volume><fpage>857</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2003.01458.x</pub-id><?supplied-pmid 12656688?><pub-id pub-id-type="pmid">12656688</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-11-00100"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname><given-names>J.</given-names></name><name><surname>Heaton</surname><given-names>K.W.</given-names></name><name><surname>Burton</surname><given-names>J.L.</given-names></name></person-group><article-title>Pruritic effect of bile salts</article-title><source>Br. Med. J.</source><year>1974</year><volume>4</volume><fpage>693</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.1136/bmj.4.5946.693</pub-id><?supplied-pmid 4441863?><pub-id pub-id-type="pmid">4441863</pub-id></element-citation></ref><ref id="B56-pharmaceuticals-11-00100"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>S.F.</given-names></name><name><surname>Roan</surname><given-names>F.</given-names></name><name><surname>Bell</surname><given-names>B.D.</given-names></name><name><surname>Stoklasek</surname><given-names>T.A.</given-names></name><name><surname>Kitajima</surname><given-names>M.</given-names></name><name><surname>Han</surname><given-names>H.</given-names></name></person-group><article-title>The biology of thymic stromal lymphopoietin (TSLP)</article-title><source>Adv. Pharmacol.</source><year>2013</year><volume>66</volume><fpage>129</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-404717-4.00004-4</pub-id><?supplied-pmid 23433457?><pub-id pub-id-type="pmid">23433457</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-11-00100"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Messaddeq</surname><given-names>N.</given-names></name><name><surname>Teletin</surname><given-names>M.</given-names></name><name><surname>Pasquali</surname><given-names>J.L.</given-names></name><name><surname>Metzger</surname><given-names>D.</given-names></name><name><surname>Chambon</surname><given-names>P.</given-names></name></person-group><article-title>Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>14795</fpage><lpage>14800</lpage><pub-id pub-id-type="doi">10.1073/pnas.0507385102</pub-id><?supplied-pmid 16199515?><pub-id pub-id-type="pmid">16199515</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-11-00100"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahern</surname><given-names>K.</given-names></name><name><surname>Gilmore</surname><given-names>E.S.</given-names></name><name><surname>Poligone</surname><given-names>B.</given-names></name></person-group><article-title>Pruritus in cutaneous T-cell lymphoma: A review</article-title><source>J. Am. Acad. Dermatol.</source><year>2012</year><volume>67</volume><fpage>760</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2011.12.021</pub-id><?supplied-pmid 22285672?><pub-id pub-id-type="pmid">22285672</pub-id></element-citation></ref><ref id="B59-pharmaceuticals-11-00100"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Q.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Convertino</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Kim</surname><given-names>Y.H.</given-names></name><name><surname>Luo</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Nackley</surname><given-names>A.</given-names></name><name><surname>Dokholyan</surname><given-names>N.V.</given-names></name><etal/></person-group><article-title>miRNA-711 Binds and Activates TRPA1 Extracellularly to Evoke Acute and Chronic Pruritus</article-title><source>Neuron</source><year>2018</year><volume>99</volume><fpage>449</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.06.039</pub-id><?supplied-pmid 30033153?><pub-id pub-id-type="pmid">30033153</pub-id></element-citation></ref><ref id="B60-pharmaceuticals-11-00100"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T.D.</given-names></name><name><surname>Hachisuka</surname><given-names>J.</given-names></name><name><surname>Ross</surname><given-names>S.E.</given-names></name></person-group><article-title>Small RNAs, but Sizable Itch: TRPA1 Activation by an Extracellular MicroRNA</article-title><source>Neuron</source><year>2018</year><volume>99</volume><fpage>421</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2018.07.040</pub-id><?supplied-pmid 30092208?><pub-id pub-id-type="pmid">30092208</pub-id></element-citation></ref><ref id="B61-pharmaceuticals-11-00100"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.E.</given-names></name><name><surname>Patapoutian</surname><given-names>A.</given-names></name><name><surname>Grandl</surname><given-names>J.</given-names></name></person-group><article-title>Single residues in the outer pore of TRPV1 and TRPV3 have temperature-dependent conformations</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e59593</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0059593</pub-id><?supplied-pmid 23555720?><pub-id pub-id-type="pmid">23555720</pub-id></element-citation></ref><ref id="B62-pharmaceuticals-11-00100"><label>62.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rosenbaum</surname><given-names>T.</given-names></name><name><surname>Simon</surname><given-names>S.A.</given-names></name></person-group><article-title>TRPV1 Receptors and Signal Transduction</article-title><source>TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades</source><person-group person-group-type="editor"><name><surname>Liedtke</surname><given-names>W.B.</given-names></name><name><surname>Heller</surname><given-names>S.</given-names></name></person-group><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2007</year></element-citation></ref><ref id="B63-pharmaceuticals-11-00100"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carnevale</surname><given-names>V.</given-names></name><name><surname>Rohacs</surname><given-names>T.</given-names></name></person-group><article-title>TRPV1: A Target for Rational Drug Design</article-title><source>Pharmaceuticals</source><year>2016</year><volume>9</volume><pub-id pub-id-type="doi">10.3390/ph9030052</pub-id><?supplied-pmid 27563913?><pub-id pub-id-type="pmid">27563913</pub-id></element-citation></ref><ref id="B64-pharmaceuticals-11-00100"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brederson</surname><given-names>J.D.</given-names></name><name><surname>Kym</surname><given-names>P.R.</given-names></name><name><surname>Szallasi</surname><given-names>A.</given-names></name></person-group><article-title>Targeting TRP channels for pain relief</article-title><source>Eur. J. Pharmacol.</source><year>2013</year><volume>716</volume><fpage>61</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2013.03.003</pub-id><?supplied-pmid 23500195?><pub-id pub-id-type="pmid">23500195</pub-id></element-citation></ref><ref id="B65-pharmaceuticals-11-00100"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>S.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Qian</surname><given-names>A.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Du</surname><given-names>G.</given-names></name><name><surname>Clark</surname><given-names>R.B.</given-names></name><name><surname>Walters</surname><given-names>E.T.</given-names></name><etal/></person-group><article-title>Retinoids activate the irritant receptor TRPV1 and produce sensory hypersensitivity</article-title><source>J. Clin. Investig.</source><year>2013</year><volume>123</volume><fpage>3941</fpage><lpage>3951</lpage><pub-id pub-id-type="doi">10.1172/JCI66413</pub-id><?supplied-pmid 23925292?><pub-id pub-id-type="pmid">23925292</pub-id></element-citation></ref><ref id="B66-pharmaceuticals-11-00100"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>W.S.</given-names></name><name><surname>Oh</surname><given-names>U.</given-names></name></person-group><article-title>Histamine-induced itch and its relationship with pain</article-title><source>Mol. Pain</source><year>2008</year><volume>4</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/1744-8069-4-29</pub-id><?supplied-pmid 18667087?><pub-id pub-id-type="pmid">18667087</pub-id></element-citation></ref><ref id="B67-pharmaceuticals-11-00100"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magerl</surname><given-names>W.</given-names></name><name><surname>Westerman</surname><given-names>R.A.</given-names></name><name><surname>Mohner</surname><given-names>B.</given-names></name><name><surname>Handwerker</surname><given-names>H.O.</given-names></name></person-group><article-title>Properties of transdermal histamine iontophoresis: Differential effects of season, gender, and body region</article-title><source>J. Investig. Dermatol.</source><year>1990</year><volume>94</volume><fpage>347</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1111/1523-1747.ep12874474</pub-id><?supplied-pmid 2307854?><pub-id pub-id-type="pmid">2307854</pub-id></element-citation></ref><ref id="B68-pharmaceuticals-11-00100"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohsawa</surname><given-names>Y.</given-names></name><name><surname>Hirasawa</surname><given-names>N.</given-names></name></person-group><article-title>The role of histamine H1 and H4 receptors in atopic dermatitis: From basic research to clinical study</article-title><source>Allergol. Int. Off. J. Jpn. Soc. Allergol.</source><year>2014</year><volume>63</volume><fpage>533</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.2332/allergolint.13-RA-0675</pub-id><?supplied-pmid 25249063?><pub-id pub-id-type="pmid">25249063</pub-id></element-citation></ref><ref id="B69-pharmaceuticals-11-00100"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shim</surname><given-names>W.S.</given-names></name><name><surname>Tak</surname><given-names>M.H.</given-names></name><name><surname>Lee</surname><given-names>M.H.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Koo</surname><given-names>J.Y.</given-names></name><name><surname>Lee</surname><given-names>C.H.</given-names></name><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Oh</surname><given-names>U.</given-names></name></person-group><article-title>TRPV1 mediates histamine-induced itching via the activation of phospholipase A2 and 12-lipoxygenase</article-title><source>J. Neurosci. Off. J. Soc. Neurosci.</source><year>2007</year><volume>27</volume><fpage>2331</fpage><lpage>2337</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4643-06.2007</pub-id><?supplied-pmid 17329430?><pub-id pub-id-type="pmid">17329430</pub-id></element-citation></ref><ref id="B70-pharmaceuticals-11-00100"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jian</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>N.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>C.</given-names></name><name><surname>Yuan</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><etal/></person-group><article-title>TRPV1 and PLC Participate in Histamine H4 Receptor-Induced Itch</article-title><source>Neural Plast.</source><year>2016</year><volume>2016</volume><fpage>1682972</fpage><pub-id pub-id-type="doi">10.1155/2016/1682972</pub-id><?supplied-pmid 26819760?><pub-id pub-id-type="pmid">26819760</pub-id></element-citation></ref><ref id="B71-pharmaceuticals-11-00100"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales-Lazaro</surname><given-names>S.L.</given-names></name><name><surname>Llorente</surname><given-names>I.</given-names></name><name><surname>Sierra-Ramirez</surname><given-names>F.</given-names></name><name><surname>Lopez-Romero</surname><given-names>A.E.</given-names></name><name><surname>Ortiz-Renteria</surname><given-names>M.</given-names></name><name><surname>Serrano-Flores</surname><given-names>B.</given-names></name><name><surname>Simon</surname><given-names>S.A.</given-names></name><name><surname>Islas</surname><given-names>L.D.</given-names></name><name><surname>Rosenbaum</surname><given-names>T.</given-names></name></person-group><article-title>Inhibition of TRPV1 channels by a naturally occurring omega-9 fatty acid reduces pain and itch</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>13092</fpage><pub-id pub-id-type="doi">10.1038/ncomms13092</pub-id><?supplied-pmid 27721373?><pub-id pub-id-type="pmid">27721373</pub-id></element-citation></ref><ref id="B72-pharmaceuticals-11-00100"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kremer</surname><given-names>A.E.</given-names></name><name><surname>Martens</surname><given-names>J.J.</given-names></name><name><surname>Kulik</surname><given-names>W.</given-names></name><name><surname>Rueff</surname><given-names>F.</given-names></name><name><surname>Kuiper</surname><given-names>E.M.</given-names></name><name><surname>van Buuren</surname><given-names>H.R.</given-names></name><name><surname>van Erpecum</surname><given-names>K.J.</given-names></name><name><surname>Kondrackiene</surname><given-names>J.</given-names></name><name><surname>Prieto</surname><given-names>J.</given-names></name><name><surname>Rust</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Lysophosphatidic acid is a potential mediator of cholestatic pruritus</article-title><source>Gastroenterology</source><year>2010</year><volume>139</volume><fpage>1008</fpage><lpage>1018</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2010.05.009</pub-id><?supplied-pmid 20546739?><pub-id pub-id-type="pmid">20546739</pub-id></element-citation></ref><ref id="B73-pharmaceuticals-11-00100"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>T.</given-names></name><name><surname>Ohata</surname><given-names>H.</given-names></name><name><surname>Momose</surname><given-names>K.</given-names></name></person-group><article-title>Itch-scratch responses induced by lysophosphatidic acid in mice</article-title><source>Pharmacology</source><year>2004</year><volume>72</volume><fpage>51</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1159/000078632</pub-id><?supplied-pmid 15292655?><pub-id pub-id-type="pmid">15292655</pub-id></element-citation></ref><ref id="B74-pharmaceuticals-11-00100"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kittaka</surname><given-names>H.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name><name><surname>Fukuta</surname><given-names>N.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name></person-group><article-title>Lysophosphatidic acid-induced itch is mediated by signalling of LPA5 receptor, phospholipase D and TRPA1/TRPV1</article-title><source>J. Physiol.</source><year>2017</year><volume>595</volume><fpage>2681</fpage><lpage>2698</lpage><pub-id pub-id-type="doi">10.1113/JP273961</pub-id><?supplied-pmid 28176353?><pub-id pub-id-type="pmid">28176353</pub-id></element-citation></ref><ref id="B75-pharmaceuticals-11-00100"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieto-Posadas</surname><given-names>A.</given-names></name><name><surname>Picazo-Juarez</surname><given-names>G.</given-names></name><name><surname>Llorente</surname><given-names>I.</given-names></name><name><surname>Jara-Oseguera</surname><given-names>A.</given-names></name><name><surname>Morales-Lazaro</surname><given-names>S.</given-names></name><name><surname>Escalante-Alcalde</surname><given-names>D.</given-names></name><name><surname>Islas</surname><given-names>L.D.</given-names></name><name><surname>Rosenbaum</surname><given-names>T.</given-names></name></person-group><article-title>Lysophosphatidic acid directly activates TRPV1 through a C-terminal binding site</article-title><source>Nat. Chem. Boil.</source><year>2011</year><volume>8</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1038/nchembio.712</pub-id><?supplied-pmid 22101604?><pub-id pub-id-type="pmid">22101604</pub-id></element-citation></ref><ref id="B76-pharmaceuticals-11-00100"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mastrolonardo</surname><given-names>M.</given-names></name><name><surname>Diaferio</surname><given-names>A.</given-names></name></person-group><article-title>Topical immunotherapy with squaric acid dibutylester: Unusual hair pigmentary changes in two cases of alopecia areata</article-title><source>J. Eur. Acad. Dermatol. Venereol. JEADV</source><year>2002</year><volume>16</volume><fpage>186</fpage><pub-id pub-id-type="doi">10.1046/j.1468-3083.2002.00392_12.x</pub-id><?supplied-pmid 12046838?><pub-id pub-id-type="pmid">12046838</pub-id></element-citation></ref><ref id="B77-pharmaceuticals-11-00100"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoller</surname><given-names>M.</given-names></name><name><surname>Freyschmidt-Paul</surname><given-names>P.</given-names></name><name><surname>Vitacolonna</surname><given-names>M.</given-names></name><name><surname>McElwee</surname><given-names>K.J.</given-names></name><name><surname>Hummel</surname><given-names>S.</given-names></name><name><surname>Hoffmann</surname><given-names>R.</given-names></name></person-group><article-title>Chronic delayed-type hypersensitivity reaction as a means to treat alopecia areata</article-title><source>Clin. Exp. Immunol.</source><year>2004</year><volume>135</volume><fpage>398</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2003.02380.x</pub-id><?supplied-pmid 15008971?><pub-id pub-id-type="pmid">15008971</pub-id></element-citation></ref><ref id="B78-pharmaceuticals-11-00100"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>N.</given-names></name><name><surname>Ma</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Han</surname><given-names>L.</given-names></name><name><surname>Fu</surname><given-names>K.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Shimada</surname><given-names>S.G.</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>LaMotte</surname><given-names>R.H.</given-names></name></person-group><article-title>Enhanced excitability of MRGPRA3- and MRGPRD-positive nociceptors in a model of inflammatory itch and pain</article-title><source>Brain</source><year>2014</year><volume>137</volume><fpage>1039</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1093/brain/awu007</pub-id><?supplied-pmid 24549959?><pub-id pub-id-type="pmid">24549959</pub-id></element-citation></ref><ref id="B79-pharmaceuticals-11-00100"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yosipovitch</surname><given-names>G.</given-names></name><name><surname>Bernhard</surname><given-names>J.D.</given-names></name></person-group><article-title>Clinical practice. Chronic pruritus</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>1625</fpage><lpage>1634</lpage><pub-id pub-id-type="doi">10.1056/NEJMcp1208814</pub-id><?supplied-pmid 23614588?><pub-id pub-id-type="pmid">23614588</pub-id></element-citation></ref><ref id="B80-pharmaceuticals-11-00100"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suto</surname><given-names>H.</given-names></name><name><surname>Matsuda</surname><given-names>H.</given-names></name><name><surname>Mitsuishi</surname><given-names>K.</given-names></name><name><surname>Hira</surname><given-names>K.</given-names></name><name><surname>Uchida</surname><given-names>T.</given-names></name><name><surname>Unno</surname><given-names>T.</given-names></name><name><surname>Ogawa</surname><given-names>H.</given-names></name><name><surname>Ra</surname><given-names>C.</given-names></name></person-group><article-title>NC/Nga mice: A mouse model for atopic dermatitis</article-title><source>Int. Arch. Allergy Immunol.</source><year>1999</year><volume>120</volume><issue>Suppl. 1</issue><fpage>70</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1159/000053599</pub-id><?supplied-pmid 10529609?><pub-id pub-id-type="pmid">10529609</pub-id></element-citation></ref><ref id="B81-pharmaceuticals-11-00100"><label>81.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cevikbas</surname><given-names>F.</given-names></name><name><surname>Kempkes</surname><given-names>C.</given-names></name><name><surname>Buhl</surname><given-names>T.</given-names></name><name><surname>Mess</surname><given-names>C.</given-names></name><name><surname>Buddenkotte</surname><given-names>J.</given-names></name><name><surname>Steinhoff</surname><given-names>M.</given-names></name></person-group><article-title>Role of Interleukin-31 and Oncostatin M in Itch and Neuroimmune Communication</article-title><source>Itch: Mechanisms and Treatment</source><person-group person-group-type="editor"><name><surname>Carstens</surname><given-names>E.</given-names></name><name><surname>Akiyama</surname><given-names>T.</given-names></name></person-group><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2014</year></element-citation></ref><ref id="B82-pharmaceuticals-11-00100"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>R.Z.</given-names></name><name><surname>Hoffman</surname><given-names>B.U.</given-names></name><name><surname>Morita</surname><given-names>T.</given-names></name><name><surname>Campos</surname><given-names>S.M.</given-names></name><name><surname>Lumpkin</surname><given-names>E.A.</given-names></name><name><surname>Brem</surname><given-names>R.B.</given-names></name><name><surname>Bautista</surname><given-names>D.M.</given-names></name></person-group><article-title>The signaling lipid sphingosine 1-phosphate regulates mechanical pain</article-title><source>eLife</source><year>2018</year><volume>7</volume><pub-id pub-id-type="doi">10.7554/eLife.33285</pub-id><?supplied-pmid 29561262?><pub-id pub-id-type="pmid">29561262</pub-id></element-citation></ref><ref id="B83-pharmaceuticals-11-00100"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weth</surname><given-names>D.</given-names></name><name><surname>Benetti</surname><given-names>C.</given-names></name><name><surname>Rauch</surname><given-names>C.</given-names></name><name><surname>Gstraunthaler</surname><given-names>G.</given-names></name><name><surname>Schmidt</surname><given-names>H.</given-names></name><name><surname>Geisslinger</surname><given-names>G.</given-names></name><name><surname>Sabbadini</surname><given-names>R.</given-names></name><name><surname>Proia</surname><given-names>R.L.</given-names></name><name><surname>Kress</surname><given-names>M.</given-names></name></person-group><article-title>Activated platelets release sphingosine 1-phosphate and induce hypersensitivity to noxious heat stimuli in vivo</article-title><source>Front. Neurosci.</source><year>2015</year><volume>9</volume><fpage>140</fpage><pub-id pub-id-type="doi">10.3389/fnins.2015.00140</pub-id><?supplied-pmid 25954148?><pub-id pub-id-type="pmid">25954148</pub-id></element-citation></ref><ref id="B84-pharmaceuticals-11-00100"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janes</surname><given-names>K.</given-names></name><name><surname>Little</surname><given-names>J.W.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Bryant</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Kamocki</surname><given-names>K.</given-names></name><name><surname>Doyle</surname><given-names>T.</given-names></name><name><surname>Snider</surname><given-names>A.</given-names></name><name><surname>Esposito</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1</article-title><source>J. Boil. Chem.</source><year>2014</year><volume>289</volume><fpage>21082</fpage><lpage>21097</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.569574</pub-id><?supplied-pmid 24876379?><pub-id pub-id-type="pmid">24876379</pub-id></element-citation></ref><ref id="B85-pharmaceuticals-11-00100"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>R.Z.</given-names></name><name><surname>Morita</surname><given-names>T.</given-names></name><name><surname>Brem</surname><given-names>R.B.</given-names></name><name><surname>Bautista</surname><given-names>D.M.</given-names></name></person-group><article-title>S1PR3 mediates itch and pain via distinct TRP channel-dependent pathways</article-title><source>J. Neurosci. Off. J. Soc. Neurosci.</source><year>2018</year><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1266-18.2018</pub-id><?supplied-pmid 30082422?><pub-id pub-id-type="pmid">30082422</pub-id></element-citation></ref><ref id="B86-pharmaceuticals-11-00100"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Ramsey</surname><given-names>I.S.</given-names></name><name><surname>Kotecha</surname><given-names>S.A.</given-names></name><name><surname>Moran</surname><given-names>M.M.</given-names></name><name><surname>Chong</surname><given-names>J.A.</given-names></name><name><surname>Lawson</surname><given-names>D.</given-names></name><name><surname>Ge</surname><given-names>P.</given-names></name><name><surname>Lilly</surname><given-names>J.</given-names></name><name><surname>Silos-Santiago</surname><given-names>I.</given-names></name><name><surname>Xie</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>TRPV3 is a calcium-permeable temperature-sensitive cation channel</article-title><source>Nature</source><year>2002</year><volume>418</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nature00882</pub-id><?supplied-pmid 12077604?><pub-id pub-id-type="pmid">12077604</pub-id></element-citation></ref><ref id="B87-pharmaceuticals-11-00100"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>S.</given-names></name><name><surname>Yoo</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>T.J.</given-names></name><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name></person-group><article-title>Farnesyl pyrophosphate is a novel pain-producing molecule via specific activation of TRPV3</article-title><source>J. Boil. Chem.</source><year>2010</year><volume>285</volume><fpage>19362</fpage><lpage>19371</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.087742</pub-id><?supplied-pmid 20395302?><pub-id pub-id-type="pmid">20395302</pub-id></element-citation></ref><ref id="B88-pharmaceuticals-11-00100"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H.</given-names></name><name><surname>Grandl</surname><given-names>J.</given-names></name><name><surname>Bandell</surname><given-names>M.</given-names></name><name><surname>Petrus</surname><given-names>M.</given-names></name><name><surname>Patapoutian</surname><given-names>A.</given-names></name></person-group><article-title>Two amino acid residues determine 2-APB sensitivity of the ion channels TRPV3 and TRPV4</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2009</year><volume>106</volume><fpage>1626</fpage><lpage>1631</lpage><pub-id pub-id-type="doi">10.1073/pnas.0812209106</pub-id><?supplied-pmid 19164517?><pub-id pub-id-type="pmid">19164517</pub-id></element-citation></ref><ref id="B89-pharmaceuticals-11-00100"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feketa</surname><given-names>V.V.</given-names></name><name><surname>Marrelli</surname><given-names>S.P.</given-names></name></person-group><article-title>Systemic Administration of the TRPV3 Ion Channel Agonist Carvacrol Induces Hypothermia in Conscious Rodents</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0141994</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0141994</pub-id><?supplied-pmid 26528923?><pub-id pub-id-type="pmid">26528923</pub-id></element-citation></ref><ref id="B90-pharmaceuticals-11-00100"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogt-Eisele</surname><given-names>A.K.</given-names></name><name><surname>Weber</surname><given-names>K.</given-names></name><name><surname>Sherkheli</surname><given-names>M.A.</given-names></name><name><surname>Vielhaber</surname><given-names>G.</given-names></name><name><surname>Panten</surname><given-names>J.</given-names></name><name><surname>Gisselmann</surname><given-names>G.</given-names></name><name><surname>Hatt</surname><given-names>H.</given-names></name></person-group><article-title>Monoterpenoid agonists of TRPV3</article-title><source>Br. J. Pharmacol.</source><year>2007</year><volume>151</volume><fpage>530</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0707245</pub-id><?supplied-pmid 17420775?><pub-id pub-id-type="pmid">17420775</pub-id></element-citation></ref><ref id="B91-pharmaceuticals-11-00100"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortar</surname><given-names>G.</given-names></name><name><surname>Morera</surname><given-names>L.</given-names></name><name><surname>Moriello</surname><given-names>A.S.</given-names></name><name><surname>Morera</surname><given-names>E.</given-names></name><name><surname>Nalli</surname><given-names>M.</given-names></name><name><surname>Di Marzo</surname><given-names>V.</given-names></name><name><surname>De Petrocellis</surname><given-names>L.</given-names></name></person-group><article-title>Modulation of thermo-transient receptor potential (thermo-TRP) channels by thymol-based compounds</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2012</year><volume>22</volume><fpage>3535</fpage><lpage>3539</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2012.03.055</pub-id><?supplied-pmid 22503249?><pub-id pub-id-type="pmid">22503249</pub-id></element-citation></ref><ref id="B92-pharmaceuticals-11-00100"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stotz</surname><given-names>S.C.</given-names></name><name><surname>Vriens</surname><given-names>J.</given-names></name><name><surname>Martyn</surname><given-names>D.</given-names></name><name><surname>Clardy</surname><given-names>J.</given-names></name><name><surname>Clapham</surname><given-names>D.E.</given-names></name></person-group><article-title>Citral sensing by Transient [corrected] receptor potential channels in dorsal root ganglion neurons</article-title><source>PLoS ONE</source><year>2008</year><volume>3</volume><elocation-id>e2082</elocation-id><pub-id pub-id-type="doi">10.1371/annotation/6ba8e9d9-0035-405e-a7c7-45ee22b2e381</pub-id><pub-id pub-id-type="pmid">18461159</pub-id></element-citation></ref><ref id="B93-pharmaceuticals-11-00100"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peier</surname><given-names>A.M.</given-names></name><name><surname>Reeve</surname><given-names>A.J.</given-names></name><name><surname>Andersson</surname><given-names>D.A.</given-names></name><name><surname>Moqrich</surname><given-names>A.</given-names></name><name><surname>Earley</surname><given-names>T.J.</given-names></name><name><surname>Hergarden</surname><given-names>A.C.</given-names></name><name><surname>Story</surname><given-names>G.M.</given-names></name><name><surname>Colley</surname><given-names>S.</given-names></name><name><surname>Hogenesch</surname><given-names>J.B.</given-names></name><name><surname>McIntyre</surname><given-names>P.</given-names></name><etal/></person-group><article-title>A heat-sensitive TRP channel expressed in keratinocytes</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>2046</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1126/science.1073140</pub-id><?supplied-pmid 12016205?><pub-id pub-id-type="pmid">12016205</pub-id></element-citation></ref><ref id="B94-pharmaceuticals-11-00100"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moqrich</surname><given-names>A.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name><name><surname>Earley</surname><given-names>T.J.</given-names></name><name><surname>Petrus</surname><given-names>M.J.</given-names></name><name><surname>Murray</surname><given-names>A.N.</given-names></name><name><surname>Spencer</surname><given-names>K.S.</given-names></name><name><surname>Andahazy</surname><given-names>M.</given-names></name><name><surname>Story</surname><given-names>G.M.</given-names></name><name><surname>Patapoutian</surname><given-names>A.</given-names></name></person-group><article-title>Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin</article-title><source>Science</source><year>2005</year><volume>307</volume><fpage>1468</fpage><lpage>1472</lpage><pub-id pub-id-type="doi">10.1126/science.1108609</pub-id><?supplied-pmid 15746429?><pub-id pub-id-type="pmid">15746429</pub-id></element-citation></ref><ref id="B95-pharmaceuticals-11-00100"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Delling</surname><given-names>M.</given-names></name><name><surname>Jun</surname><given-names>J.C.</given-names></name><name><surname>Clapham</surname><given-names>D.E.</given-names></name></person-group><article-title>Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels</article-title><source>Nat. Neurosci.</source><year>2006</year><volume>9</volume><fpage>628</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1038/nn1692</pub-id><?supplied-pmid 16617338?><pub-id pub-id-type="pmid">16617338</pub-id></element-citation></ref><ref id="B96-pharmaceuticals-11-00100"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto-Kasai</surname><given-names>E.</given-names></name><name><surname>Yasui</surname><given-names>K.</given-names></name><name><surname>Shichijo</surname><given-names>M.</given-names></name><name><surname>Sakata</surname><given-names>T.</given-names></name><name><surname>Yoshioka</surname><given-names>T.</given-names></name></person-group><article-title>Impact of TRPV3 on the development of allergic dermatitis as a dendritic cell modulator</article-title><source>Exp. Dermatol.</source><year>2013</year><volume>22</volume><fpage>820</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1111/exd.12273</pub-id><?supplied-pmid 24164484?><pub-id pub-id-type="pmid">24164484</pub-id></element-citation></ref><ref id="B97-pharmaceuticals-11-00100"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y.S.</given-names></name><name><surname>Cho</surname><given-names>S.I.</given-names></name><name><surname>Choi</surname><given-names>M.G.</given-names></name><name><surname>Choi</surname><given-names>Y.H.</given-names></name><name><surname>Kwak</surname><given-names>I.S.</given-names></name><name><surname>Park</surname><given-names>C.W.</given-names></name><name><surname>Kim</surname><given-names>H.O.</given-names></name></person-group><article-title>Increased expression of three types of transient receptor potential channels (TRPA1, TRPV4 and TRPV3) in burn scars with post-burn pruritus</article-title><source>Acta Dermato-Venereol.</source><year>2015</year><volume>95</volume><fpage>20</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.2340/00015555-1858</pub-id><?supplied-pmid 24695993?><pub-id pub-id-type="pmid">24695993</pub-id></element-citation></ref><ref id="B98-pharmaceuticals-11-00100"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Mack</surname><given-names>M.R.</given-names></name><name><surname>Du</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name><name><surname>Qian</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch</article-title><source>J. Allergy Clin. Immunol.</source><year>2018</year><volume>141</volume><fpage>608</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2017.05.051</pub-id><?supplied-pmid 28807414?><pub-id pub-id-type="pmid">28807414</pub-id></element-citation></ref><ref id="B99-pharmaceuticals-11-00100"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>X.</given-names></name><name><surname>Jin</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Shen</surname><given-names>D.</given-names></name><name><surname>Dong</surname><given-names>X.P.</given-names></name><name><surname>Samie</surname><given-names>M.A.</given-names></name><name><surname>Knoff</surname><given-names>J.</given-names></name><name><surname>Eisinger</surname><given-names>B.</given-names></name><name><surname>Liu</surname><given-names>M.L.</given-names></name><name><surname>Huang</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>TRP channel regulates EGFR signaling in hair morphogenesis and skin barrier formation</article-title><source>Cell</source><year>2010</year><volume>141</volume><fpage>331</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.03.013</pub-id><?supplied-pmid 20403327?><pub-id pub-id-type="pmid">20403327</pub-id></element-citation></ref><ref id="B100-pharmaceuticals-11-00100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mickle</surname><given-names>A.D.</given-names></name><name><surname>Shepherd</surname><given-names>A.J.</given-names></name><name><surname>Mohapatra</surname><given-names>D.P.</given-names></name></person-group><article-title>Sensory TRP channels: The key transducers of nociception and pain</article-title><source>Prog. Mol. Boil. Transl. Sci.</source><year>2015</year><volume>131</volume><fpage>73</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/bs.pmbts.2015.01.002</pub-id></element-citation></ref><ref id="B101-pharmaceuticals-11-00100"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilius</surname><given-names>B.</given-names></name><name><surname>Biro</surname><given-names>T.</given-names></name><name><surname>Owsianik</surname><given-names>G.</given-names></name></person-group><article-title>TRPV3: Time to decipher a poorly understood family member!</article-title><source>J. Physiol.</source><year>2014</year><volume>592</volume><fpage>295</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2013.255968</pub-id><?supplied-pmid 23836684?><pub-id pub-id-type="pmid">23836684</pub-id></element-citation></ref><ref id="B102-pharmaceuticals-11-00100"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asakawa</surname><given-names>M.</given-names></name><name><surname>Yoshioka</surname><given-names>T.</given-names></name><name><surname>Matsutani</surname><given-names>T.</given-names></name><name><surname>Hikita</surname><given-names>I.</given-names></name><name><surname>Suzuki</surname><given-names>M.</given-names></name><name><surname>Oshima</surname><given-names>I.</given-names></name><name><surname>Tsukahara</surname><given-names>K.</given-names></name><name><surname>Arimura</surname><given-names>A.</given-names></name><name><surname>Horikawa</surname><given-names>T.</given-names></name><name><surname>Hirasawa</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Association of a mutation in TRPV3 with defective hair growth in rodents</article-title><source>J. Investig. Dermatol.</source><year>2006</year><volume>126</volume><fpage>2664</fpage><lpage>2672</lpage><pub-id pub-id-type="doi">10.1038/sj.jid.5700468</pub-id><?supplied-pmid 16858425?><pub-id pub-id-type="pmid">16858425</pub-id></element-citation></ref><ref id="B103-pharmaceuticals-11-00100"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>R.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>M.X.</given-names></name></person-group><article-title>The TRPV3 mutation associated with the hairless phenotype in rodents is constitutively active</article-title><source>Cell Calcium</source><year>2008</year><volume>43</volume><fpage>334</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2007.06.004</pub-id><?supplied-pmid 17706768?><pub-id pub-id-type="pmid">17706768</pub-id></element-citation></ref><ref id="B104-pharmaceuticals-11-00100"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagai</surname><given-names>H.</given-names></name><name><surname>Takaoka</surname><given-names>Y.</given-names></name><name><surname>Sugano</surname><given-names>A.</given-names></name><name><surname>Nakamachi</surname><given-names>Y.</given-names></name><name><surname>Kawano</surname><given-names>S.</given-names></name><name><surname>Nishigori</surname><given-names>C.</given-names></name></person-group><article-title>Identification of a heterozygous p.Gly568Val missense mutation in the TRPV3 gene in a Japanese patient with Olmsted syndrome: In silico analysis of TRPV3</article-title><source>J. Dermatol.</source><year>2017</year><volume>44</volume><fpage>1059</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1111/1346-8138.13844</pub-id><?supplied-pmid 28391651?><pub-id pub-id-type="pmid">28391651</pub-id></element-citation></ref><ref id="B105-pharmaceuticals-11-00100"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atherton</surname><given-names>D.J.</given-names></name><name><surname>Sutton</surname><given-names>C.</given-names></name><name><surname>Jones</surname><given-names>B.M.</given-names></name></person-group><article-title>Mutilating palmoplantar keratoderma with periorificial keratotic plaques (Olmsted&#x02019;s syndrome)</article-title><source>Br. J. Dermatol.</source><year>1990</year><volume>122</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2133.1990.tb08271.x</pub-id><?supplied-pmid 2138494?><pub-id pub-id-type="pmid">2138494</pub-id></element-citation></ref><ref id="B106-pharmaceuticals-11-00100"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>S.E.</given-names></name><name><surname>Lee</surname><given-names>S.E.</given-names></name><name><surname>Kim</surname><given-names>S.C.</given-names></name></person-group><article-title>Olmsted Syndrome Caused by a Heterozygous p.Gly568Val Missense Mutation in TRPV3 Gene</article-title><source>Yonsei Med. J.</source><year>2018</year><volume>59</volume><fpage>341</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.3349/ymj.2018.59.2.341</pub-id><?supplied-pmid 29436206?><pub-id pub-id-type="pmid">29436206</pub-id></element-citation></ref><ref id="B107-pharmaceuticals-11-00100"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibasaki</surname><given-names>K.</given-names></name><name><surname>Sugio</surname><given-names>S.</given-names></name><name><surname>Takao</surname><given-names>K.</given-names></name><name><surname>Yamanaka</surname><given-names>A.</given-names></name><name><surname>Miyakawa</surname><given-names>T.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name><name><surname>Ishizaki</surname><given-names>Y.</given-names></name></person-group><article-title>TRPV4 activation at the physiological temperature is a critical determinant of neuronal excitability and behavior</article-title><source>Pflugers Arch. Eur. J. Physiol.</source><year>2015</year><volume>467</volume><fpage>2495</fpage><lpage>2507</lpage><pub-id pub-id-type="doi">10.1007/s00424-015-1726-0</pub-id><?supplied-pmid 26250433?><pub-id pub-id-type="pmid">26250433</pub-id></element-citation></ref><ref id="B108-pharmaceuticals-11-00100"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sokabe</surname><given-names>T.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name></person-group><article-title>The TRPV4 cation channel: A molecule linking skin temperature and barrier function</article-title><source>Commun. Integr. Boil.</source><year>2010</year><volume>3</volume><fpage>619</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.4161/cib.3.6.13461</pub-id><?supplied-pmid 21331258?><pub-id pub-id-type="pmid">21331258</pub-id></element-citation></ref><ref id="B109-pharmaceuticals-11-00100"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamenko</surname><given-names>M.</given-names></name><name><surname>Zaika</surname><given-names>O.</given-names></name><name><surname>Boukelmoune</surname><given-names>N.</given-names></name><name><surname>O&#x02019;Neil</surname><given-names>R.G.</given-names></name><name><surname>Pochynyuk</surname><given-names>O.</given-names></name></person-group><article-title>Deciphering physiological role of the mechanosensitive TRPV4 channel in the distal nephron</article-title><source>Am. J. Physiol. Ren. Physiol.</source><year>2015</year><volume>308</volume><fpage>F275</fpage><lpage>F286</lpage><pub-id pub-id-type="doi">10.1152/ajprenal.00485.2014</pub-id><?supplied-pmid 25503733?><pub-id pub-id-type="pmid">25503733</pub-id></element-citation></ref><ref id="B110-pharmaceuticals-11-00100"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>C.</given-names></name><name><surname>Cevikbas</surname><given-names>F.</given-names></name><name><surname>Pasolli</surname><given-names>H.A.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Kong</surname><given-names>W.</given-names></name><name><surname>Kempkes</surname><given-names>C.</given-names></name><name><surname>Parekh</surname><given-names>P.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Kontchou</surname><given-names>N.A.</given-names></name><name><surname>Yeh</surname><given-names>I.</given-names></name><etal/></person-group><article-title>UVB radiation generates sunburn pain and affects skin by activating epidermal TRPV4 ion channels and triggering endothelin-1 signaling</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>E3225</fpage><lpage>E3234</lpage><pub-id pub-id-type="doi">10.1073/pnas.1312933110</pub-id><?supplied-pmid 23929777?><pub-id pub-id-type="pmid">23929777</pub-id></element-citation></ref><ref id="B111-pharmaceuticals-11-00100"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clapham</surname><given-names>D.E.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name><name><surname>Montell</surname><given-names>C.</given-names></name><name><surname>Schultz</surname><given-names>G.</given-names></name></person-group><article-title>International Union of Pharmacology. XLIX. Nomenclature and structure-function relationships of transient receptor potential channels</article-title><source>Pharmacol. Rev.</source><year>2005</year><volume>57</volume><fpage>427</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1124/pr.57.4.6</pub-id><?supplied-pmid 16382100?><pub-id pub-id-type="pmid">16382100</pub-id></element-citation></ref><ref id="B112-pharmaceuticals-11-00100"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raddatz</surname><given-names>N.</given-names></name><name><surname>Castillo</surname><given-names>J.P.</given-names></name><name><surname>Gonzalez</surname><given-names>C.</given-names></name><name><surname>Alvarez</surname><given-names>O.</given-names></name><name><surname>Latorre</surname><given-names>R.</given-names></name></person-group><article-title>Temperature and voltage coupling to channel opening in transient receptor potential melastatin 8 (TRPM8)</article-title><source>J. Boil. Chem.</source><year>2014</year><volume>289</volume><fpage>35438</fpage><lpage>35454</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.612713</pub-id><?supplied-pmid 25352597?><pub-id pub-id-type="pmid">25352597</pub-id></element-citation></ref><ref id="B113-pharmaceuticals-11-00100"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherkheli</surname><given-names>M.A.</given-names></name><name><surname>Gisselmann</surname><given-names>G.</given-names></name><name><surname>Vogt-Eisele</surname><given-names>A.K.</given-names></name><name><surname>Doerner</surname><given-names>J.F.</given-names></name><name><surname>Hatt</surname><given-names>H.</given-names></name></person-group><article-title>Menthol derivative WS-12 selectively activates transient receptor potential melastatin-8 (TRPM8) ion channels</article-title><source>Pak. J. Pharm. Sci.</source><year>2008</year><volume>21</volume><fpage>370</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">18930858</pub-id></element-citation></ref><ref id="B114-pharmaceuticals-11-00100"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caceres</surname><given-names>A.I.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Jabba</surname><given-names>S.V.</given-names></name><name><surname>Achanta</surname><given-names>S.</given-names></name><name><surname>Morris</surname><given-names>J.B.</given-names></name><name><surname>Jordt</surname><given-names>S.E.</given-names></name></person-group><article-title>Transient Receptor Potential Cation Channel Subfamily M Member 8 channels mediate the anti-inflammatory effects of eucalyptol</article-title><source>Br. J. Pharmacol.</source><year>2017</year><volume>174</volume><fpage>867</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1111/bph.13760</pub-id><?supplied-pmid 28240768?><pub-id pub-id-type="pmid">28240768</pub-id></element-citation></ref><ref id="B115-pharmaceuticals-11-00100"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bautista</surname><given-names>D.M.</given-names></name><name><surname>Siemens</surname><given-names>J.</given-names></name><name><surname>Glazer</surname><given-names>J.M.</given-names></name><name><surname>Tsuruda</surname><given-names>P.R.</given-names></name><name><surname>Basbaum</surname><given-names>A.I.</given-names></name><name><surname>Stucky</surname><given-names>C.L.</given-names></name><name><surname>Jordt</surname><given-names>S.E.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name></person-group><article-title>The menthol receptor TRPM8 is the principal detector of environmental cold</article-title><source>Nature</source><year>2007</year><volume>448</volume><fpage>204</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1038/nature05910</pub-id><?supplied-pmid 17538622?><pub-id pub-id-type="pmid">17538622</pub-id></element-citation></ref><ref id="B116-pharmaceuticals-11-00100"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babes</surname><given-names>A.</given-names></name><name><surname>Ciobanu</surname><given-names>A.C.</given-names></name><name><surname>Neacsu</surname><given-names>C.</given-names></name><name><surname>Babes</surname><given-names>R.M.</given-names></name></person-group><article-title>TRPM8, a sensor for mild cooling in mammalian sensory nerve endings</article-title><source>Curr. Pharm. Biotechnol.</source><year>2011</year><volume>12</volume><fpage>78</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.2174/138920111793937835</pub-id><?supplied-pmid 20932256?><pub-id pub-id-type="pmid">20932256</pub-id></element-citation></ref><ref id="B117-pharmaceuticals-11-00100"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denda</surname><given-names>M.</given-names></name><name><surname>Tsutsumi</surname><given-names>M.</given-names></name><name><surname>Denda</surname><given-names>S.</given-names></name></person-group><article-title>Topical application of TRPM8 agonists accelerates skin permeability barrier recovery and reduces epidermal proliferation induced by barrier insult: Role of cold-sensitive TRP receptors in epidermal permeability barrier homoeostasis</article-title><source>Exp. Dermatol.</source><year>2010</year><volume>19</volume><fpage>791</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0625.2010.01154.x</pub-id><?supplied-pmid 20636355?><pub-id pub-id-type="pmid">20636355</pub-id></element-citation></ref><ref id="B118-pharmaceuticals-11-00100"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagerstrom</surname><given-names>M.C.</given-names></name><name><surname>Rogoz</surname><given-names>K.</given-names></name><name><surname>Abrahamsen</surname><given-names>B.</given-names></name><name><surname>Persson</surname><given-names>E.</given-names></name><name><surname>Reinius</surname><given-names>B.</given-names></name><name><surname>Nordenankar</surname><given-names>K.</given-names></name><name><surname>Olund</surname><given-names>C.</given-names></name><name><surname>Smith</surname><given-names>C.</given-names></name><name><surname>Mendez</surname><given-names>J.A.</given-names></name><name><surname>Chen</surname><given-names>Z.F.</given-names></name><etal/></person-group><article-title>VGLUT2-dependent sensory neurons in the TRPV1 population regulate pain and itch</article-title><source>Neuron</source><year>2010</year><volume>68</volume><fpage>529</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.016</pub-id><?supplied-pmid 21040852?><pub-id pub-id-type="pmid">21040852</pub-id></element-citation></ref><ref id="B119-pharmaceuticals-11-00100"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Abdel Samad</surname><given-names>O.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Duan</surname><given-names>B.</given-names></name><name><surname>Tong</surname><given-names>Q.</given-names></name><name><surname>Lopes</surname><given-names>C.</given-names></name><name><surname>Ji</surname><given-names>R.R.</given-names></name><name><surname>Lowell</surname><given-names>B.B.</given-names></name><name><surname>Ma</surname><given-names>Q.</given-names></name></person-group><article-title>VGLUT2-dependent glutamate release from nociceptors is required to sense pain and suppress itch</article-title><source>Neuron</source><year>2010</year><volume>68</volume><fpage>543</fpage><lpage>556</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.008</pub-id><?supplied-pmid 21040853?><pub-id pub-id-type="pmid">21040853</pub-id></element-citation></ref><ref id="B120-pharmaceuticals-11-00100"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palkar</surname><given-names>R.</given-names></name><name><surname>Ongun</surname><given-names>S.</given-names></name><name><surname>Catich</surname><given-names>E.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><name><surname>Borad</surname><given-names>N.</given-names></name><name><surname>Sarkisian</surname><given-names>A.</given-names></name><name><surname>McKemy</surname><given-names>D.D.</given-names></name></person-group><article-title>Cooling Relief of Acute and Chronic Itch Requires TRPM8 Channels and Neurons</article-title><source>J. Investig. Dermatol.</source><year>2018</year><volume>138</volume><fpage>1391</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2017.12.025</pub-id><?supplied-pmid 29288650?><pub-id pub-id-type="pmid">29288650</pub-id></element-citation></ref><ref id="B121-pharmaceuticals-11-00100"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Jordt</surname><given-names>S.E.</given-names></name></person-group><article-title>Cooling the Itch via TRPM8</article-title><source>J. Investig. Dermatol.</source><year>2018</year><volume>138</volume><fpage>1254</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1016/j.jid.2018.01.020</pub-id><?supplied-pmid 29793621?><pub-id pub-id-type="pmid">29793621</pub-id></element-citation></ref><ref id="B122-pharmaceuticals-11-00100"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Proudfoot</surname><given-names>C.J.</given-names></name><name><surname>Garry</surname><given-names>E.M.</given-names></name><name><surname>Cottrell</surname><given-names>D.F.</given-names></name><name><surname>Rosie</surname><given-names>R.</given-names></name><name><surname>Anderson</surname><given-names>H.</given-names></name><name><surname>Robertson</surname><given-names>D.C.</given-names></name><name><surname>Fleetwood-Walker</surname><given-names>S.M.</given-names></name><name><surname>Mitchell</surname><given-names>R.</given-names></name></person-group><article-title>Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain</article-title><source>Curr. Boil.</source><year>2006</year><volume>16</volume><fpage>1591</fpage><lpage>1605</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2006.07.061</pub-id><?supplied-pmid 16920620?><pub-id pub-id-type="pmid">16920620</pub-id></element-citation></ref><ref id="B123-pharmaceuticals-11-00100"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stander</surname><given-names>S.</given-names></name><name><surname>Augustin</surname><given-names>M.</given-names></name><name><surname>Roggenkamp</surname><given-names>D.</given-names></name><name><surname>Blome</surname><given-names>C.</given-names></name><name><surname>Heitkemper</surname><given-names>T.</given-names></name><name><surname>Worthmann</surname><given-names>A.C.</given-names></name><name><surname>Neufang</surname><given-names>G.</given-names></name></person-group><article-title>Novel TRPM8 agonist cooling compound against chronic itch: Results from a randomized, double-blind, controlled, pilot study in dry skin</article-title><source>J. Eur. Acad. Dermatol. Venereol. JEADV</source><year>2017</year><volume>31</volume><fpage>1064</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1111/jdv.14041</pub-id><?supplied-pmid 27862339?><pub-id pub-id-type="pmid">27862339</pub-id></element-citation></ref><ref id="B124-pharmaceuticals-11-00100"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naono-Nakayama</surname><given-names>R.</given-names></name><name><surname>Sunakawa</surname><given-names>N.</given-names></name><name><surname>Ikeda</surname><given-names>T.</given-names></name><name><surname>Nishimori</surname><given-names>T.</given-names></name></person-group><article-title>Differential effects of substance P or hemokinin-1 on transient receptor potential channels, TRPV1, TRPA1 and TRPM8, in the rat</article-title><source>Neuropeptides</source><year>2010</year><volume>44</volume><fpage>57</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.npep.2009.10.002</pub-id><?supplied-pmid 19926130?><pub-id pub-id-type="pmid">19926130</pub-id></element-citation></ref><ref id="B125-pharmaceuticals-11-00100"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>J.H.</given-names></name><name><surname>Choi</surname><given-names>H.K.</given-names></name><name><surname>Kim</surname><given-names>S.J.</given-names></name></person-group><article-title>Topical TRPM8 agonist (icilin) relieved vulva pruritus originating from lichen sclerosus et atrophicus</article-title><source>Acta Dermato-Venereol.</source><year>2012</year><volume>92</volume><fpage>561</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.2340/00015555-1244</pub-id><?supplied-pmid 22042233?><pub-id pub-id-type="pmid">22042233</pub-id></element-citation></ref><ref id="B126-pharmaceuticals-11-00100"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bromm</surname><given-names>B.</given-names></name><name><surname>Scharein</surname><given-names>E.</given-names></name><name><surname>Darsow</surname><given-names>U.</given-names></name><name><surname>Ring</surname><given-names>J.</given-names></name></person-group><article-title>Effects of menthol and cold on histamine-induced itch and skin reactions in man</article-title><source>Neurosci. Lett.</source><year>1995</year><volume>187</volume><fpage>157</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(95)11362-Z</pub-id><pub-id pub-id-type="pmid">7624016</pub-id></element-citation></ref><ref id="B127-pharmaceuticals-11-00100"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnock</surname><given-names>J.K.</given-names></name><name><surname>Morris</surname><given-names>D.W.</given-names></name></person-group><article-title>Adverse cutaneous reactions to antidepressants</article-title><source>Am. J. Clin. Dermatol.</source><year>2002</year><volume>3</volume><fpage>329</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.2165/00128071-200203050-00005</pub-id><?supplied-pmid 12069639?><pub-id pub-id-type="pmid">12069639</pub-id></element-citation></ref><ref id="B128-pharmaceuticals-11-00100"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Cho</surname><given-names>P.S.</given-names></name><name><surname>Tonello</surname><given-names>R.</given-names></name><name><surname>Lee</surname><given-names>H.K.</given-names></name><name><surname>Jang</surname><given-names>J.H.</given-names></name><name><surname>Park</surname><given-names>G.Y.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name><name><surname>Park</surname><given-names>C.K.</given-names></name><name><surname>Jung</surname><given-names>S.J.</given-names></name><name><surname>Berta</surname><given-names>T.</given-names></name></person-group><article-title>Peripheral serotonin receptor 2B and transient receptor potential channel 4 mediate pruritus to serotonergic antidepressants in mice</article-title><source>J. Allergy Clin. Immunol.</source><year>2018</year><pub-id pub-id-type="doi">10.1016/j.jaci.2018.05.031</pub-id><?supplied-pmid 29920354?><pub-id pub-id-type="pmid">29920354</pub-id></element-citation></ref><ref id="B129-pharmaceuticals-11-00100"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNamara</surname><given-names>C.R.</given-names></name><name><surname>Mandel-Brehm</surname><given-names>J.</given-names></name><name><surname>Bautista</surname><given-names>D.M.</given-names></name><name><surname>Siemens</surname><given-names>J.</given-names></name><name><surname>Deranian</surname><given-names>K.L.</given-names></name><name><surname>Zhao</surname><given-names>M.</given-names></name><name><surname>Hayward</surname><given-names>N.J.</given-names></name><name><surname>Chong</surname><given-names>J.A.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name><name><surname>Moran</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>TRPA1 mediates formalin-induced pain</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2007</year><volume>104</volume><fpage>13525</fpage><lpage>13530</lpage><pub-id pub-id-type="doi">10.1073/pnas.0705924104</pub-id><?supplied-pmid 17686976?><pub-id pub-id-type="pmid">17686976</pub-id></element-citation></ref><ref id="B130-pharmaceuticals-11-00100"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Joshi</surname><given-names>S.K.</given-names></name><name><surname>DiDomenico</surname><given-names>S.</given-names></name><name><surname>Perner</surname><given-names>R.J.</given-names></name><name><surname>Mikusa</surname><given-names>J.P.</given-names></name><name><surname>Gauvin</surname><given-names>D.M.</given-names></name><name><surname>Segreti</surname><given-names>J.A.</given-names></name><name><surname>Han</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>X.F.</given-names></name><name><surname>Niforatos</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation</article-title><source>Pain</source><year>2011</year><volume>152</volume><fpage>1165</fpage><lpage>1172</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2011.01.049</pub-id><?supplied-pmid 21402443?><pub-id pub-id-type="pmid">21402443</pub-id></element-citation></ref><ref id="B131-pharmaceuticals-11-00100"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrus</surname><given-names>M.</given-names></name><name><surname>Peier</surname><given-names>A.M.</given-names></name><name><surname>Bandell</surname><given-names>M.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name><name><surname>Huynh</surname><given-names>T.</given-names></name><name><surname>Olney</surname><given-names>N.</given-names></name><name><surname>Jegla</surname><given-names>T.</given-names></name><name><surname>Patapoutian</surname><given-names>A.</given-names></name></person-group><article-title>A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition</article-title><source>Mol. Pain</source><year>2007</year><volume>3</volume><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/1744-8069-3-40</pub-id><?supplied-pmid 18086313?><pub-id pub-id-type="pmid">18086313</pub-id></element-citation></ref><ref id="B132-pharmaceuticals-11-00100"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schenkel</surname><given-names>L.B.</given-names></name><name><surname>Olivieri</surname><given-names>P.R.</given-names></name><name><surname>Boezio</surname><given-names>A.A.</given-names></name><name><surname>Deak</surname><given-names>H.L.</given-names></name><name><surname>Emkey</surname><given-names>R.</given-names></name><name><surname>Graceffa</surname><given-names>R.F.</given-names></name><name><surname>Gunaydin</surname><given-names>H.</given-names></name><name><surname>Guzman-Perez</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Teffera</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity</article-title><source>J. Med. Chem.</source><year>2016</year><volume>59</volume><fpage>2794</fpage><lpage>2809</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.6b00039</pub-id><?supplied-pmid 26942860?><pub-id pub-id-type="pmid">26942860</pub-id></element-citation></ref><ref id="B133-pharmaceuticals-11-00100"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavva</surname><given-names>N.R.</given-names></name><name><surname>Tamir</surname><given-names>R.</given-names></name><name><surname>Qu</surname><given-names>Y.</given-names></name><name><surname>Klionsky</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>T.J.</given-names></name><name><surname>Immke</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>D.</given-names></name><name><surname>Vanderah</surname><given-names>T.W.</given-names></name><name><surname>Porreca</surname><given-names>F.</given-names></name><etal/></person-group><article-title>AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2005</year><volume>313</volume><fpage>474</fpage><lpage>484</lpage><pub-id pub-id-type="doi">10.1124/jpet.104.079855</pub-id><?supplied-pmid 15615864?><pub-id pub-id-type="pmid">15615864</pub-id></element-citation></ref><ref id="B134-pharmaceuticals-11-00100"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunthorpe</surname><given-names>M.J.</given-names></name><name><surname>Rami</surname><given-names>H.K.</given-names></name><name><surname>Jerman</surname><given-names>J.C.</given-names></name><name><surname>Smart</surname><given-names>D.</given-names></name><name><surname>Gill</surname><given-names>C.H.</given-names></name><name><surname>Soffin</surname><given-names>E.M.</given-names></name><name><surname>Luis Hannan</surname><given-names>S.</given-names></name><name><surname>Lappin</surname><given-names>S.C.</given-names></name><name><surname>Egerton</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist</article-title><source>Neuropharmacology</source><year>2004</year><volume>46</volume><fpage>133</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/S0028-3908(03)00305-8</pub-id><pub-id pub-id-type="pmid">14654105</pub-id></element-citation></ref><ref id="B135-pharmaceuticals-11-00100"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yun</surname><given-names>J.W.</given-names></name><name><surname>Seo</surname><given-names>J.A.</given-names></name><name><surname>Jeong</surname><given-names>Y.S.</given-names></name><name><surname>Bae</surname><given-names>I.H.</given-names></name><name><surname>Jang</surname><given-names>W.H.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>S.Y.</given-names></name><name><surname>Shin</surname><given-names>S.S.</given-names></name><name><surname>Woo</surname><given-names>B.Y.</given-names></name><name><surname>Lee</surname><given-names>K.W.</given-names></name><etal/></person-group><article-title>TRPV1 antagonist can suppress the atopic dermatitis-like symptoms by accelerating skin barrier recovery</article-title><source>J. Dermatol. Sci.</source><year>2011</year><volume>62</volume><fpage>8</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2010.10.014</pub-id><?supplied-pmid 21345654?><pub-id pub-id-type="pmid">21345654</pub-id></element-citation></ref><ref id="B136-pharmaceuticals-11-00100"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunthorpe</surname><given-names>M.J.</given-names></name><name><surname>Hannan</surname><given-names>S.L.</given-names></name><name><surname>Smart</surname><given-names>D.</given-names></name><name><surname>Jerman</surname><given-names>J.C.</given-names></name><name><surname>Arpino</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>G.D.</given-names></name><name><surname>Brough</surname><given-names>S.</given-names></name><name><surname>Wright</surname><given-names>J.</given-names></name><name><surname>Egerton</surname><given-names>J.</given-names></name><name><surname>Lappin</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title>Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2007</year><volume>321</volume><fpage>1183</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1124/jpet.106.116657</pub-id><?supplied-pmid 17392405?><pub-id pub-id-type="pmid">17392405</pub-id></element-citation></ref><ref id="B137-pharmaceuticals-11-00100"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>S.</given-names></name><name><surname>Yoo</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>T.J.</given-names></name><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name></person-group><article-title>17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception</article-title><source>Br. J. Pharmacol.</source><year>2012</year><volume>165</volume><fpage>683</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01568.x</pub-id><?supplied-pmid 21718307?><pub-id pub-id-type="pmid">21718307</pub-id></element-citation></ref><ref id="B138-pharmaceuticals-11-00100"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everaerts</surname><given-names>W.</given-names></name><name><surname>Zhen</surname><given-names>X.</given-names></name><name><surname>Ghosh</surname><given-names>D.</given-names></name><name><surname>Vriens</surname><given-names>J.</given-names></name><name><surname>Gevaert</surname><given-names>T.</given-names></name><name><surname>Gilbert</surname><given-names>J.P.</given-names></name><name><surname>Hayward</surname><given-names>N.J.</given-names></name><name><surname>McNamara</surname><given-names>C.R.</given-names></name><name><surname>Xue</surname><given-names>F.</given-names></name><name><surname>Moran</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>19084</fpage><lpage>19089</lpage><pub-id pub-id-type="doi">10.1073/pnas.1005333107</pub-id><?supplied-pmid 20956320?><pub-id pub-id-type="pmid">20956320</pub-id></element-citation></ref><ref id="B139-pharmaceuticals-11-00100"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>M.</given-names></name><name><surname>Bao</surname><given-names>W.</given-names></name><name><surname>Behm</surname><given-names>D.J.</given-names></name><name><surname>Brooks</surname><given-names>C.A.</given-names></name><name><surname>Bury</surname><given-names>M.J.</given-names></name><name><surname>Dowdell</surname><given-names>S.E.</given-names></name><name><surname>Eidam</surname><given-names>H.S.</given-names></name><name><surname>Fox</surname><given-names>R.M.</given-names></name><name><surname>Goodman</surname><given-names>K.B.</given-names></name><name><surname>Holt</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4</article-title><source>ACS Med. Chem. Lett.</source><year>2017</year><volume>8</volume><fpage>549</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.7b00094</pub-id><?supplied-pmid 28523109?><pub-id pub-id-type="pmid">28523109</pub-id></element-citation></ref><ref id="B140-pharmaceuticals-11-00100"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>M.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Kustov</surname><given-names>M.</given-names></name><name><surname>Tian</surname><given-names>J.B.</given-names></name><name><surname>Stevens</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Long</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels</article-title><source>J. Boil. Chem.</source><year>2011</year><volume>286</volume><fpage>33436</fpage><lpage>33446</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.274167</pub-id><?supplied-pmid 21795696?><pub-id pub-id-type="pmid">21795696</pub-id></element-citation></ref><ref id="B141-pharmaceuticals-11-00100"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Just</surname><given-names>S.</given-names></name><name><surname>Chenard</surname><given-names>B.L.</given-names></name><name><surname>Ceci</surname><given-names>A.</given-names></name><name><surname>Strassmaier</surname><given-names>T.</given-names></name><name><surname>Chong</surname><given-names>J.A.</given-names></name><name><surname>Blair</surname><given-names>N.T.</given-names></name><name><surname>Gallaschun</surname><given-names>R.J.</given-names></name><name><surname>Del Camino</surname><given-names>D.</given-names></name><name><surname>Cantin</surname><given-names>S.</given-names></name><name><surname>D&#x02019;Amours</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Treatment with HC-070, a potent inhibitor of TRPC4 and TRPC5, leads to anxiolytic and antidepressant effects in mice</article-title><source>PLoS ONE</source><year>2018</year><volume>13</volume><elocation-id>e0191225</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0191225</pub-id><?supplied-pmid 29385160?><pub-id pub-id-type="pmid">29385160</pub-id></element-citation></ref><ref id="B142-pharmaceuticals-11-00100"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKemy</surname><given-names>D.D.</given-names></name><name><surname>Neuhausser</surname><given-names>W.M.</given-names></name><name><surname>Julius</surname><given-names>D.</given-names></name></person-group><article-title>Identification of a cold receptor reveals a general role for TRP channels in thermosensation</article-title><source>Nature</source><year>2002</year><volume>416</volume><fpage>52</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1038/nature719</pub-id><?supplied-pmid 11882888?><pub-id pub-id-type="pmid">11882888</pub-id></element-citation></ref><ref id="B143-pharmaceuticals-11-00100"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takaishi</surname><given-names>M.</given-names></name><name><surname>Fujita</surname><given-names>F.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name><name><surname>Yamamoto</surname><given-names>S.</given-names></name><name><surname>Sawada Shimizu</surname><given-names>M.</given-names></name><name><surname>Hatai Uotsu</surname><given-names>C.</given-names></name><name><surname>Shimizu</surname><given-names>M.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name></person-group><article-title>1,8-cineole, a TRPM8 agonist, is a novel natural antagonist of human TRPA1</article-title><source>Mol. Pain</source><year>2012</year><volume>8</volume><fpage>86</fpage><pub-id pub-id-type="doi">10.1186/1744-8069-8-86</pub-id><?supplied-pmid 23192000?><pub-id pub-id-type="pmid">23192000</pub-id></element-citation></ref><ref id="B144-pharmaceuticals-11-00100"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>R.</given-names></name><name><surname>Goncalves</surname><given-names>L.</given-names></name><name><surname>Leveridge</surname><given-names>M.</given-names></name><name><surname>Mack</surname><given-names>S.R.</given-names></name><name><surname>Hendrick</surname><given-names>A.</given-names></name><name><surname>Brice</surname><given-names>N.L.</given-names></name><name><surname>Dickenson</surname><given-names>A.H.</given-names></name></person-group><article-title>Anti-hyperalgesic effects of a novel TRPM8 agonist in neuropathic rats: A comparison with topical menthol</article-title><source>Pain</source><year>2014</year><volume>155</volume><fpage>2097</fpage><lpage>2107</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2014.07.022</pub-id><?supplied-pmid 25083927?><pub-id pub-id-type="pmid">25083927</pub-id></element-citation></ref><ref id="B145-pharmaceuticals-11-00100"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodding</surname><given-names>M.</given-names></name><name><surname>Wissenbach</surname><given-names>U.</given-names></name><name><surname>Flockerzi</surname><given-names>V.</given-names></name></person-group><article-title>Characterisation of TRPM8 as a pharmacophore receptor</article-title><source>Cell Calcium</source><year>2007</year><volume>42</volume><fpage>618</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/j.ceca.2007.03.005</pub-id><?supplied-pmid 17517434?><pub-id pub-id-type="pmid">17517434</pub-id></element-citation></ref><ref id="B146-pharmaceuticals-11-00100"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noyer</surname><given-names>L.</given-names></name><name><surname>Grolez</surname><given-names>G.P.</given-names></name><name><surname>Prevarskaya</surname><given-names>N.</given-names></name><name><surname>Gkika</surname><given-names>D.</given-names></name><name><surname>Lemonnier</surname><given-names>L.</given-names></name></person-group><article-title>TRPM8 and prostate: A cold case?</article-title><source>Pflugers Arch. Eur. J. Physiol.</source><year>2018</year><pub-id pub-id-type="doi">10.1007/s00424-018-2169-1</pub-id><?supplied-pmid 29926226?><pub-id pub-id-type="pmid">29926226</pub-id></element-citation></ref><ref id="B147-pharmaceuticals-11-00100"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Hackos</surname><given-names>D.H.</given-names></name></person-group><article-title>TRPA1 as a drug target&#x02014;Promise and challenges</article-title><source>Naunyn-Schmiedeberg&#x02019;s Arch. Pharmacol.</source><year>2015</year><volume>388</volume><fpage>451</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1007/s00210-015-1088-3</pub-id><?supplied-pmid 25640188?><pub-id pub-id-type="pmid">25640188</pub-id></element-citation></ref><ref id="B148-pharmaceuticals-11-00100"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patricio</surname><given-names>E.S.</given-names></name><name><surname>Costa</surname><given-names>R.</given-names></name><name><surname>Figueiredo</surname><given-names>C.P.</given-names></name><name><surname>Gers-Barlag</surname><given-names>K.</given-names></name><name><surname>Bicca</surname><given-names>M.A.</given-names></name><name><surname>Manjavachi</surname><given-names>M.N.</given-names></name><name><surname>Segat</surname><given-names>G.C.</given-names></name><name><surname>Gentry</surname><given-names>C.</given-names></name><name><surname>Luiz</surname><given-names>A.P.</given-names></name><name><surname>Fernandes</surname><given-names>E.S.</given-names></name><etal/></person-group><article-title>Mechanisms Underlying the Scratching Behavior Induced by the Activation of Proteinase-Activated Receptor-4 in Mice</article-title><source>J. Investig. Dermatol.</source><year>2015</year><volume>135</volume><fpage>2484</fpage><lpage>2491</lpage><pub-id pub-id-type="doi">10.1038/jid.2015.183</pub-id><?supplied-pmid 25955385?><pub-id pub-id-type="pmid">25955385</pub-id></element-citation></ref><ref id="B149-pharmaceuticals-11-00100"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>M.H.</given-names></name><name><surname>Oh</surname><given-names>S.Y.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Lou</surname><given-names>H.</given-names></name><name><surname>Myers</surname><given-names>A.C.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Zheng</surname><given-names>T.</given-names></name></person-group><article-title>TRPA1-dependent pruritus in IL-13-induced chronic atopic dermatitis</article-title><source>J. Immunol.</source><year>2013</year><volume>191</volume><fpage>5371</fpage><lpage>5382</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1300300</pub-id><?supplied-pmid 24140646?><pub-id pub-id-type="pmid">24140646</pub-id></element-citation></ref><ref id="B150-pharmaceuticals-11-00100"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Escalera</surname><given-names>J.</given-names></name><name><surname>Balakrishna</surname><given-names>S.</given-names></name><name><surname>Fan</surname><given-names>L.</given-names></name><name><surname>Caceres</surname><given-names>A.I.</given-names></name><name><surname>Robinson</surname><given-names>E.</given-names></name><name><surname>Sui</surname><given-names>A.</given-names></name><name><surname>McKay</surname><given-names>M.C.</given-names></name><name><surname>McAlexander</surname><given-names>M.A.</given-names></name><name><surname>Herrick</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>TRPA1 controls inflammation and pruritogen responses in allergic contact dermatitis</article-title><source>FASEB J. Off. Publ. Fed. Am. Soc. Exp. Boil.</source><year>2013</year><volume>27</volume><fpage>3549</fpage><lpage>3563</lpage><pub-id pub-id-type="doi">10.1096/fj.13-229948</pub-id><?supplied-pmid 23722916?><pub-id pub-id-type="pmid">23722916</pub-id></element-citation></ref><ref id="B151-pharmaceuticals-11-00100"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>E.S.</given-names></name><name><surname>Vong</surname><given-names>C.T.</given-names></name><name><surname>Quek</surname><given-names>S.</given-names></name><name><surname>Cheong</surname><given-names>J.</given-names></name><name><surname>Awal</surname><given-names>S.</given-names></name><name><surname>Gentry</surname><given-names>C.</given-names></name><name><surname>Aubdool</surname><given-names>A.A.</given-names></name><name><surname>Liang</surname><given-names>L.</given-names></name><name><surname>Bodkin</surname><given-names>J.V.</given-names></name><name><surname>Bevan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Superoxide generation and leukocyte accumulation: Key elements in the mediation of leukotriene B(4)-induced itch by transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1</article-title><source>FASEB J. Off. Publ. Fed. Am. Soc. Exp. Boil.</source><year>2013</year><volume>27</volume><fpage>1664</fpage><lpage>1673</lpage><pub-id pub-id-type="doi">10.1096/fj.12-221218</pub-id><?supplied-pmid 23271050?><pub-id pub-id-type="pmid">23271050</pub-id></element-citation></ref><ref id="B152-pharmaceuticals-11-00100"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>S.</given-names></name><name><surname>Tominaga</surname><given-names>M.</given-names></name></person-group><article-title>Evolutionary tuning of TRPA1 and TRPV1 thermal and chemical sensitivity in vertebrates</article-title><source>Temperature</source><year>2017</year><volume>4</volume><fpage>141</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1080/23328940.2017.1315478</pub-id><?supplied-pmid 28680930?><pub-id pub-id-type="pmid">28680930</pub-id></element-citation></ref><ref id="B153-pharmaceuticals-11-00100"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saarnilehto</surname><given-names>M.</given-names></name><name><surname>Chapman</surname><given-names>H.</given-names></name><name><surname>Savinko</surname><given-names>T.</given-names></name><name><surname>Lindstedt</surname><given-names>K.</given-names></name><name><surname>Lauerma</surname><given-names>A.I.</given-names></name><name><surname>Koivisto</surname><given-names>A.</given-names></name></person-group><article-title>Contact sensitizer 2,4-dinitrochlorobenzene is a highly potent human TRPA1 agonist</article-title><source>Allergy</source><year>2014</year><volume>69</volume><fpage>1424</fpage><lpage>1427</lpage><pub-id pub-id-type="doi">10.1111/all.12488</pub-id><?supplied-pmid 25041656?><pub-id pub-id-type="pmid">25041656</pub-id></element-citation></ref><ref id="B154-pharmaceuticals-11-00100"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>R.</given-names></name><name><surname>Marotta</surname><given-names>D.M.</given-names></name><name><surname>Manjavachi</surname><given-names>M.N.</given-names></name><name><surname>Fernandes</surname><given-names>E.S.</given-names></name><name><surname>Lima-Garcia</surname><given-names>J.F.</given-names></name><name><surname>Paszcuk</surname><given-names>A.F.</given-names></name><name><surname>Quintao</surname><given-names>N.L.</given-names></name><name><surname>Juliano</surname><given-names>L.</given-names></name><name><surname>Brain</surname><given-names>S.D.</given-names></name><name><surname>Calixto</surname><given-names>J.B.</given-names></name></person-group><article-title>Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice</article-title><source>Br. J. Pharmacol.</source><year>2008</year><volume>154</volume><fpage>1094</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1038/bjp.2008.172</pub-id><?supplied-pmid 18454165?><pub-id pub-id-type="pmid">18454165</pub-id></element-citation></ref><ref id="B155-pharmaceuticals-11-00100"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>R.A.</given-names></name><name><surname>Robertson</surname><given-names>J.</given-names></name><name><surname>Mistry</surname><given-names>H.</given-names></name><name><surname>McCallum</surname><given-names>S.</given-names></name><name><surname>Fernando</surname><given-names>D.</given-names></name><name><surname>Wyres</surname><given-names>M.</given-names></name><name><surname>Yosipovitch</surname><given-names>G.</given-names></name></person-group><article-title>A randomised trial evaluating the effects of the TRPV1 antagonist SB705498 on pruritus induced by histamine, and cowhage challenge in healthy volunteers</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e100610</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0100610</pub-id><?supplied-pmid 25047038?><pub-id pub-id-type="pmid">25047038</pub-id></element-citation></ref><ref id="B156-pharmaceuticals-11-00100"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chizh</surname><given-names>B.A.</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>M.B.</given-names></name><name><surname>Napolitano</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Brooke</surname><given-names>A.C.</given-names></name><name><surname>Aylott</surname><given-names>M.C.</given-names></name><name><surname>Bullman</surname><given-names>J.N.</given-names></name><name><surname>Gray</surname><given-names>E.J.</given-names></name><name><surname>Lai</surname><given-names>R.Y.</given-names></name><name><surname>Williams</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans</article-title><source>Pain</source><year>2007</year><volume>132</volume><fpage>132</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2007.06.006</pub-id><?supplied-pmid 17659837?><pub-id pub-id-type="pmid">17659837</pub-id></element-citation></ref><ref id="B157-pharmaceuticals-11-00100"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reilly</surname><given-names>R.M.</given-names></name><name><surname>Kym</surname><given-names>P.R.</given-names></name></person-group><article-title>Analgesic potential of TRPV3 antagonists</article-title><source>Curr. Top. Med. Chem.</source><year>2011</year><volume>11</volume><fpage>2210</fpage><lpage>2215</lpage><pub-id pub-id-type="doi">10.2174/156802611796904889</pub-id><?supplied-pmid 21671874?><pub-id pub-id-type="pmid">21671874</pub-id></element-citation></ref><ref id="B158-pharmaceuticals-11-00100"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broad</surname><given-names>L.M.</given-names></name><name><surname>Mogg</surname><given-names>A.J.</given-names></name><name><surname>Eberle</surname><given-names>E.</given-names></name><name><surname>Tolley</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>D.L.</given-names></name><name><surname>Knopp</surname><given-names>K.L.</given-names></name></person-group><article-title>TRPV3 in Drug Development</article-title><source>Pharmaceuticals</source><year>2016</year><volume>9</volume><pub-id pub-id-type="doi">10.3390/ph9030055</pub-id><?supplied-pmid 27618069?><pub-id pub-id-type="pmid">27618069</pub-id></element-citation></ref><ref id="B159-pharmaceuticals-11-00100"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ariel</surname><given-names>A.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name></person-group><article-title>Resolvins and protectins in the termination program of acute inflammation</article-title><source>Trends Immunol.</source><year>2007</year><volume>28</volume><fpage>176</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1016/j.it.2007.02.007</pub-id><?supplied-pmid 17337246?><pub-id pub-id-type="pmid">17337246</pub-id></element-citation></ref><ref id="B160-pharmaceuticals-11-00100"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z.Z.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Park</surname><given-names>J.Y.</given-names></name><name><surname>Berta</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Serhan</surname><given-names>C.N.</given-names></name><name><surname>Ji</surname><given-names>R.R.</given-names></name></person-group><article-title>Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions</article-title><source>Nat. Med.</source><year>2010</year><volume>16</volume><fpage>592</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1038/nm.2123</pub-id><?supplied-pmid 20383154?><pub-id pub-id-type="pmid">20383154</pub-id></element-citation></ref><ref id="B161-pharmaceuticals-11-00100"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanju</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>W.</given-names></name><name><surname>Yeo</surname><given-names>M.</given-names></name><name><surname>Lee</surname><given-names>S.H.</given-names></name><name><surname>Romac</surname><given-names>J.</given-names></name><name><surname>Shahid</surname><given-names>R.</given-names></name><name><surname>Fan</surname><given-names>P.</given-names></name><name><surname>Gooden</surname><given-names>D.M.</given-names></name><name><surname>Simon</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>Small molecule dual-inhibitors of TRPV4 and TRPA1 for attenuation of inflammation and pain</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>26894</fpage><pub-id pub-id-type="doi">10.1038/srep26894</pub-id><?supplied-pmid 27247148?><pub-id pub-id-type="pmid">27247148</pub-id></element-citation></ref><ref id="B162-pharmaceuticals-11-00100"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Qu</surname><given-names>C.</given-names></name><name><surname>Miller</surname><given-names>M.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Thakur</surname><given-names>D.P.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Deng</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Identification and optimization of 2-aminobenzimidazole derivatives as novel inhibitors of TRPC4 and TRPC5 channels</article-title><source>Br. J. Pharmacol.</source><year>2015</year><volume>172</volume><fpage>3495</fpage><lpage>3509</lpage><pub-id pub-id-type="doi">10.1111/bph.13140</pub-id><?supplied-pmid 25816897?><pub-id pub-id-type="pmid">25816897</pub-id></element-citation></ref><ref id="B163-pharmaceuticals-11-00100"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panahi</surname><given-names>Y.</given-names></name><name><surname>Davoodi</surname><given-names>S.M.</given-names></name><name><surname>Khalili</surname><given-names>H.</given-names></name><name><surname>Dashti-Khavidaki</surname><given-names>S.</given-names></name><name><surname>Bigdeli</surname><given-names>M.</given-names></name></person-group><article-title>Phenol and menthol in the treatment of chronic skin lesions following mustard gas exposure</article-title><source>Singap. Med. J.</source><year>2007</year><volume>48</volume><fpage>392</fpage><lpage>395</lpage></element-citation></ref><ref id="B164-pharmaceuticals-11-00100"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frolich</surname><given-names>M.</given-names></name><name><surname>Enk</surname><given-names>A.</given-names></name><name><surname>Diepgen</surname><given-names>T.L.</given-names></name><name><surname>Weisshaar</surname><given-names>E.</given-names></name></person-group><article-title>Successful treatment of therapy-resistant pruritus in lichen amyloidosis with menthol</article-title><source>Acta Dermato-Venereol.</source><year>2009</year><volume>89</volume><fpage>524</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.2340/00015555-0725</pub-id><?supplied-pmid 19734984?><pub-id pub-id-type="pmid">19734984</pub-id></element-citation></ref><ref id="B165-pharmaceuticals-11-00100"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haught</surname><given-names>J.M.</given-names></name><name><surname>Jukic</surname><given-names>D.M.</given-names></name><name><surname>English</surname><given-names>J.C.</given-names><suffix>3rd</suffix></name></person-group><article-title>Hydroxyethyl starch-induced pruritus relieved by a combination of menthol and camphor</article-title><source>J. Am. Acad. Dermatol.</source><year>2008</year><volume>59</volume><fpage>151</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2008.03.034</pub-id><?supplied-pmid 18455262?><pub-id pub-id-type="pmid">18455262</pub-id></element-citation></ref><ref id="B166-pharmaceuticals-11-00100"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macpherson</surname><given-names>L.J.</given-names></name><name><surname>Hwang</surname><given-names>S.W.</given-names></name><name><surname>Miyamoto</surname><given-names>T.</given-names></name><name><surname>Dubin</surname><given-names>A.E.</given-names></name><name><surname>Patapoutian</surname><given-names>A.</given-names></name><name><surname>Story</surname><given-names>G.M.</given-names></name></person-group><article-title>More than cool: Promiscuous relationships of menthol and other sensory compounds</article-title><source>Mol. Cell. Neurosci.</source><year>2006</year><volume>32</volume><fpage>335</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2006.05.005</pub-id><?supplied-pmid 16829128?><pub-id pub-id-type="pmid">16829128</pub-id></element-citation></ref><ref id="B167-pharmaceuticals-11-00100"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rawls</surname><given-names>S.M.</given-names></name><name><surname>Gomez</surname><given-names>T.</given-names></name><name><surname>Ding</surname><given-names>Z.</given-names></name><name><surname>Raffa</surname><given-names>R.B.</given-names></name></person-group><article-title>Differential behavioral effect of the TRPM8/TRPA1 channel agonist icilin (AG-3-5)</article-title><source>Eur. J. Pharmacol.</source><year>2007</year><volume>575</volume><fpage>103</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2007.07.060</pub-id><?supplied-pmid 17765220?><pub-id pub-id-type="pmid">17765220</pub-id></element-citation></ref><ref id="B168-pharmaceuticals-11-00100"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardiner</surname><given-names>J.C.</given-names></name><name><surname>Kirkup</surname><given-names>A.J.</given-names></name><name><surname>Curry</surname><given-names>J.</given-names></name><name><surname>Humphreys</surname><given-names>S.</given-names></name><name><surname>O&#x02019;Regan</surname><given-names>P.</given-names></name><name><surname>Postlethwaite</surname><given-names>M.</given-names></name><name><surname>Young</surname><given-names>K.C.</given-names></name><name><surname>Kitching</surname><given-names>L.</given-names></name><name><surname>Ethell</surname><given-names>B.T.</given-names></name><name><surname>Winpenny</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The role of TRPM8 in the Guinea-pig bladder-cooling reflex investigated using a novel TRPM8 antagonist</article-title><source>Eur. J. Pharmacol.</source><year>2014</year><volume>740</volume><fpage>398</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2014.07.022</pub-id><?supplied-pmid 25058909?><pub-id pub-id-type="pmid">25058909</pub-id></element-citation></ref><ref id="B169-pharmaceuticals-11-00100"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeFalco</surname><given-names>J.</given-names></name><name><surname>Duncton</surname><given-names>M.A.</given-names></name><name><surname>Emerling</surname><given-names>D.</given-names></name></person-group><article-title>TRPM8 biology and medicinal chemistry</article-title><source>Curr. Top. Med. Chem.</source><year>2011</year><volume>11</volume><fpage>2237</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.2174/156802611796904933</pub-id><?supplied-pmid 21671871?><pub-id pub-id-type="pmid">21671871</pub-id></element-citation></ref><ref id="B170-pharmaceuticals-11-00100"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Fan</surname><given-names>L.</given-names></name><name><surname>Balakrishna</surname><given-names>S.</given-names></name><name><surname>Sui</surname><given-names>A.</given-names></name><name><surname>Morris</surname><given-names>J.B.</given-names></name><name><surname>Jordt</surname><given-names>S.E.</given-names></name></person-group><article-title>TRPM8 is the principal mediator of menthol-induced analgesia of acute and inflammatory pain</article-title><source>Pain</source><year>2013</year><volume>154</volume><fpage>2169</fpage><lpage>2177</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2013.06.043</pub-id><?supplied-pmid 23820004?><pub-id pub-id-type="pmid">23820004</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceuticals-11-00100-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Transient receptor potential (TRP) channels and itch signaling. Six TRP channels are implicated in itch signaling, including TRPA1, TRPV1, TRPV3, TRPV4, TRPM8, and TRPC4. All itch-related TRP channels are expressed in keratinocytes and/or primary sensory neurons. TRPA1 is required for itch evoked by chloroquine (CQ), bovine adrenal medulla 8&#x02013;22 peptide (BAM8-22), 5-hydroxytryptamine (5-HT), bile acid, and thymic stromal lymphopoietin (TSLP) which can be released from keratinocytes through protease-activated receptor 2 (PAR2) activation. These pruritogens bind to their respective G protein-coupled receptors (GPCRs): Mas-related G protein-coupled receptor member A3 (MrgprA3), MrgprC11, 5-hydroxytryptamine receptor 7(HTR7), G protein-coupled bile acid receptor Gpbar1 (TGR5), and thymic stromal lymphopoietin receptor (TSLPR). Phospholipase C (PLC) and G&#x003b2;&#x003b3; signaling downstream from these receptors contribute to TRPA1 activation. TRPA1 also mediates miR-711-induced itch through direct activation. TRPV1 is required for histamine-evoked itch, whereby histamine receptor 1 (H1R) and histamine receptor 4 (H4R) activate TRPV1 through the PLC signaling pathway. TRPV1 also participates in cyclic phosphatidic acid-induced itch through direct activation. Both TRPA1 and TRPV1 are involved in squaric acid dibutylester (SADBE)- and lysophosphatidic acid (LPA)-induced itch through direct activation. In addition, both TRPA1 and TRPV1 are required for interleukin-31 (IL-31)- and sphingosine 1-phosphate (S1P)-related itch, but the detailed mechanisms remain unresolved. Mutations of amino acid residues in TRPV3 have been associated with Olmsted syndrome (OS), suggesting a potential role in itch signaling. Emerging data implicate TRPV4 in both histaminergic and non-histaminergic itch, but results from different research groups are controversial [<xref rid="B27-pharmaceuticals-11-00100" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-11-00100" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceuticals-11-00100" ref-type="bibr">29</xref>]. HTR2B and TRPC4 are involved in selective serotonin reuptake inhibitor (SSRI)-evoked pruritus. Unlike other TRP channels, TRPM8 activation inhibits itch and is required for cooling- and menthol-mediated itch inhibition.</p></caption><graphic xlink:href="pharmaceuticals-11-00100-g001"/></fig><table-wrap id="pharmaceuticals-11-00100-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-11-00100-t001_Table 1</object-id><label>Table 1</label><caption><p>Ligands of itch-related TRP channels.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ligands</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Targets</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Potencies</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HC-030031</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 6.2 and 5.3 &#x003bc;M for AITC- and formalin-evoked Ca<sup>2+</sup> influx, respectively.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B129-pharmaceuticals-11-00100" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A-967079</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 0.3 &#x003bc;M for mTRPA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B130-pharmaceuticals-11-00100" ref-type="bibr">130</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AP18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 3.1 &#x003bc;M and 4.5 &#x003bc;M for hTRPA1 and mTRPA1, respectively</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B131-pharmaceuticals-11-00100" ref-type="bibr">131</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AM-0902</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 24 nM for hTRPA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B132-pharmaceuticals-11-00100" ref-type="bibr">132</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AMG9810</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPV1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 24.5 nM for hTRPV1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B133-pharmaceuticals-11-00100" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SB366791</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPV1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 5.7 nM and 7.5 nM for hTRPV1 and rTRPV1, respectively</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B134-pharmaceuticals-11-00100" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PAC-14028</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPV1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 55.0 nM for rTRPV1 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B135-pharmaceuticals-11-00100" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SB-705498</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPV1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 3 nM for capsaicin-induced activation of hTRPV1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B136-pharmaceuticals-11-00100" ref-type="bibr">136</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17R-RvD1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPV3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 398 nM for hTRPV3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B137-pharmaceuticals-11-00100" ref-type="bibr">137</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HC-067047</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPV4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 48 nM, 133 nM, and 17 nM for hTRPV4, rTRPV4, and mTRPV4, respectively</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B138-pharmaceuticals-11-00100" ref-type="bibr">138</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GSK2193874</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPV4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 40 nM and 2 nM for hTRPV4 and rTRPV4, respectively</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B139-pharmaceuticals-11-00100" ref-type="bibr">139</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ML204</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPC4<break/>TRPC5<break/>TRPC6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 0.96 &#x003bc;M for mTRPC4&#x003b2; and about 65% inhibition of TRPC5 and 38% inhibition of TRPC6 at 10 &#x003bc;M</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B140-pharmaceuticals-11-00100" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HC-070</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPC4<break/>TRPC5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub> = 46.0 nM for hTRPC4<break/>IC<sub>50</sub> = 9.3 nM for hTRPC5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B141-pharmaceuticals-11-00100" ref-type="bibr">141</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,8-cineole</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPM8<break/>TRPA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EC<sub>50</sub> = 3.4&#x02009;mM for TRPM8<break/>IC<sub>50</sub> = 3.4 mM for TRPA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B142-pharmaceuticals-11-00100" ref-type="bibr">142</xref>,<xref rid="B143-pharmaceuticals-11-00100" ref-type="bibr">143</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M8-Ag</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPM8<break/>TRPA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EC<sub>50</sub> = 45 nM for TRPM8<break/>EC<sub>50</sub> &#x0003e; 4 &#x003bc;M for TRPA1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B144-pharmaceuticals-11-00100" ref-type="bibr">144</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WS-12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPM8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EC<sub>50</sub> = 193 nM for hTRPM8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B145-pharmaceuticals-11-00100" ref-type="bibr">145</xref>,<xref rid="B146-pharmaceuticals-11-00100" ref-type="bibr">146</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>